Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  24-JUN-2020An Open-Label, Single-Dose Study to Evaluate the 
Pharmacokinetics of Islatravir (MK-8591) in Subjects with Severe 
Renal Impairment
PRODUCT: MK-8591  1
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD) .
Protocol Title: An Open -Label, Single -Dose Study  to Evaluate the Pharmacokinetics of 
Islatravir ( MK-8591) in Subjects with Severe Renal I mpairment
This protocol amendment is applicable only to Germany.
Protocol Number: 026-02
Compound Number: MK-8591
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889- 0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND 128, 595
EudraCT 2020- 000153- 27
Approval Date: 24 June 2020¬†
¬† 05JCP2
PRODUCT: MK-8591  2
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
Title:Date¬†
¬† 05JCP2
PRODUCT: MK-8591  3
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment - 02 24- Jun-2020 Inclusion criteria w ereclarified to define ‚Äògood health‚Äô with respect to blood pressure 
limits and laboratory  values for healthy and renally  impaired participants (country 
specific, German y only).
Amendment - 01 19- May-2020 Exclusion criteria and ECG abnormality  criteria to ad just the threshold value of QTc for 
all participants and adjust the upper limit of heart rate for healthy  participants were 
modified . The eGFR threshold for healthy  participants was also adjusted to align with 
the European guidance and the CKD -EPI equation will be used for all participants.  
Exclusion criteria was also added to ensure enrolled subjects are at low risk for HIV 
infection (country  specific, US only ).  
Original Protocol 10-Feb-2020 Not applicable¬†
¬† 05JCP2
PRODUCT: MK-8591  4
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
PROTOCOL AMENDMENT S UMMARY OF CHANGES 
Amendment: 02
Overall Rationale for the Amendments:
Inclusion criteria w ereclarified to define ‚Äògood health‚Äô with respect to blood pressure limits and laboratory  values for healthy  and 
renall y impaired participants (country  specific, Germany  only).
Summary of Changes Table:
Section # and Name Description of Change Brief Ration ale 
Section 5.1.1 I nclusion 
Criteria for Health y 
Participants,
Section 5.1.2 I nclusion 
Criteria for Renally  
Impaired ParticipantsClarify  that the inclusion criteria apply  to all healthy  or 
renall y impaired participants and additional inclusion 
criteria that appl y to Germany  only can be found in 
Appendix 7 Country  Specific Requirements.Country  specific requirements have been 
added for German y only.
Section 10.7 Country  
Specific RequirementsDefine good health in inclusion # 1 and #2 for healthy
participants as follows: 
With respect to blood pressure, ‚Äúgood health‚Äù is defined 
as sy stolic blood pressure not more than 139 mm Hg and 
the diastolic blood pressure not more than 89 mm Hg.
With respect to specific laboratory results, ‚Äúgood health‚Äù 
is defined so that ALT, AST, and bilirubin values (except 
if consistent with Gilbert‚Äôs disease) should not exceed the 
upper limit of normal (ULN); any  other abnormal 
laboratory  parameters must be considered not clinically  
significant.Inclusion criteria was clarified to define 
‚Äògood health‚Äô with respect to blood pressure 
limits and laboratory  values for healthy  and 
renall y impaired participants (country 
specific, German y only).¬†
¬† 05JCP2
PRODUCT: MK-8591  5
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Section # and Name Description of Change Brief Ration ale 
Define good health in incl usion # 1 and #2 for renally  
impaired participants as follows: 
With respect to blood pressure, ‚Äúgood health‚Äù is defined 
as sy stolic blood pressure not more than 160 mm Hg and 
diastolic blood pressure not more than 100 mm Hg.
With respect to specific laboratory  results, ‚Äúgood health‚Äù 
is defined so that only clinically  significant lab 
abnormalities associated with renal disease are accept able; 
any other abnormal laboratory parameters must be 
considered not clinically  significant for inclusion.¬†
¬† 05JCP2
PRODUCT: MK-8591  6
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 13
1.1 Synopsis ................................................................................................................. 13
1.2 Schema .................................................................................................................. 16
1.3 Schedule of Activities ........................................................................................... 17
2 INTRODUCTION .......................................................................................................... 21
2.1 Study Rationale ....................................................................................................21
2.2 Background .......................................................................................................... 21
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 21
2.2.2 Preclinical and Clinical Studies ...................................................................22
2.2.3 Ongoing Clinical Studies ............................................................................. 23
2.3 Benefit/Risk Assessment ...................................................................................... 24
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 24
4 STUDY DESIGN ............................................................................................................ 25
4.1 Overall Design ......................................................................................................25
4.2 Scientific Rationale for Study Design ................................................................ .26
4.2.1 Rationale for Endpoints ............................................................................... 27
4.2.1.1 Efficacy  Endpoints ............................................................................. 27
4.2.1.2 Safety  Endpoints ................................................................................ 27
4.2.1.3 Pharmacokinetic Endpoints ............................................................... 27
4.2.1.4 Pharmacod ynamic Endpoints............................................................. 28
4.2.1.5 Planned Exploratory  Biomarker Research .........................................28
4.2.1.5.1 Planned Genetic Anal ysis........................................................ 28
4.2.1.6 Future Biomedical Research .............................................................. 28
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 29
4.3 Justification for Dose ........................................................................................... 29
4.4 Beginning and End of Study Definition ............................................................. 29
4.4.1 Clinical Criteria for Early Study Termination ............................................. 30
5 STUDY POPULATION ................................................................................................ 30
5.1 Inclusion Criteria ................................................................................................ .30
5.1.1 Inclusion Criteria for Healthy  Participants .................................................. 30
5.1.2 Inclusion Criteria for Renally  Impaired Participants ...................................32
5.2 Exclusion Criteria ................................................................................................ 34
5.2.1 Exclusion Criteria for Healthy  Participants ................................................. 34¬†
¬† 05JCP2
PRODUCT: MK-8591  7
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
5.2.2 Exclusion Criteria for Renally  Impaired Participants .................................. 36
5.3 Lifestyle Considerations ...................................................................................... 38
5.3.1 Meals and Dietary Restrictions ....................................................................38
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions .............................................. 38
5.3.2.1 Caffeine Restrictions .......................................................................... 38
5.3.2.2 Alcohol Restrictions ........................................................................... 39
5.3.2.3 Smoking Restrictions ......................................................................... 39
5.3.3 Activity  Restrictions .................................................................................... 39
5.4 Screen Failures .....................................................................................................39
5.5 Participant Replacement Strategy ......................................................................39
6 STUDY INTERVENTION ............................................................................................ 40
6.1 Study Intervention(s) Administered ...................................................................40
6.2 Preparation/Handling/Storage/Accountability ................................................. 42
6.2.1 Dose Preparation .......................................................................................... 42
6.2.2 Handling, Storage, and Accountability ........................................................ 42
6.3 Measures to Minimize Bias: Randomization and Blind ing.............................. 43
6.3.1 Intervention Assignment.............................................................................. 43
6.3.2 Stratification ................................................................................................ .43
6.3.3 Blinding........................................................................................................43
6.4 Study Intervention Compliance .......................................................................... 43
6.5 Concomitant Therapy .......................................................................................... 43
6.5.1 Rescue Medications and Supportive Care ................................................... 44
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 45
6.6.1 Stopping R ules............................................................................................. 45
6.7 Intervention After the End of the Study ............................................................ 45
6.8 Clinical Supplies Disclosure ................................................................................ 45
7 DISCONTINUATION OF S TUDY INTERVENTION AND PARTICIPANT 
WITHDRAWAL ............................................................................................................ 45
7.1 Discontinuation of Study Intervention ............................................................... 45
7.2 Participant Withdrawal From the Study ........................................................... 45
7.3 Lost to Follow -up................................................................................................ .46
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 46
8.1 Administrative and General Procedures ........................................................... 47
8.1.1 Informed Consent ......................................................................................... 47
8.1.1.1 General Informed Consent ................................................................ .47
8.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 47
8.1.2 Inclusion/Exclusion Criteria ........................................................................48¬†
¬† 05JCP2
PRODUCT: MK-8591  8
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.1.3 Participant Identification Card ..................................................................... 48
8.1.4 Medical History ........................................................................................... 48
8.1.5 Prior and Concomitant Medications Review ............................................... 48
8.1.5.1 Prior Medications ............................................................................... 48
8.1.5.2 Concomitant Medications ..................................................................48
8.1.6 Assignment of Screening Number ............................................................... 48
8.1.7 Assignment of Treatment/Randomization Number .....................................49
8.1.8 Study  Intervention Administration .............................................................. 49
8.1.8.1 Timing of Dose Administration ......................................................... 49
8.1.9 Discontinuation and Withdrawal ................................................................ .49
8.1.9.1 Withdrawal From Future Biomedical Research ................................ 50
8.1.10 Participant Blinding/Unblinding ..................................................................50
8.1.11 Domiciling ...................................................................................................50
8.1.12 Calibration of Equipment ............................................................................. 50
8.2 Efficacy/Immunogenicity Assessments .............................................................. 51
8.3 Safety Assessments ............................................................................................... 51
8.3.1 Physical Examinations ................................................................................. 51
8.3.2 Vital Signs....................................................................................................51
8.3.2.1 Resting Vital Signs ............................................................................ 52
8.3.3 Electrocardiograms ...................................................................................... 52
8.3.4 Clinical Safety  Laboratory  Assessments ..................................................... 53
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 54
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 54
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......55
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...56
8.4.4 Regulatory  Reporti ng Requirements for SAE ............................................. 56
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 56
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ 56
8.4.7 Events of Clinical I nterest ............................................................................ 57
8.5 Treatment of Overdose ........................................................................................ 57
8.6 Pharmacokinetics................................................................................................ .57
8.6.1 Blood Collection for Plasma I SL and PBMC I SL-TP................................ .57
8.7 Pharmacodynamics .............................................................................................. 58
8.8 Biomarkers ........................................................................................................... 58
8.8.1 Planned Genetic Anal ysis Sam ple Collection .............................................. 58¬†
¬† 05JCP2
PRODUCT: MK-8591  9
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.9 Future Biomedical Research Sample Collection ............................................... 58
8.10 Visit Requirements ............................................................................................... 58
8.10.1 Screening......................................................................................................58
8.10.2 Treatment Period .......................................................................................... 59
8.10.3 Discontinued Participants Continuing to be Monitored in the Study .......... 59
8.10.4 Poststudy ......................................................................................................59
8.10.5 Critical Procedures Based on Study  Objectiv es: Timing of Procedure .......59
8.10.6 Study  Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 60
9 STATISTICAL ANALYSIS PLAN ............................................................................. 61
9.1 Statistical Analysis Plan Summary.....................................................................61
9.2 Responsibility for Analyses ................................................................................. 62
9.3 Hypotheses/Estimation ........................................................................................ 62
9.4 Analysis Endpoints ............................................................................................... 62
9.5 Analysis Populations ............................................................................................ 63
9.6 Statistical Methods ............................................................................................... 63
9.7 Interim Analyses ..................................................................................................65
9.8 Multiplicity ........................................................................................................... 65
9.9 Sample Size and Power Calculations ................................................................ .65
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................66
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........66
10.1.1 Code of Conduct f or Clinical Trials ............................................................. 66
10.1.2 Financial Disclosure ..................................................................................... 68
10.1.3 Data Protection ............................................................................................. 68
10.1.3.1 Confidentiality  of Data ......................................................................69
10.1.3.2 Confidentiality  of Participant Records ............................................... 69
10.1.3.3 Confidentiality  of IRB/IEC I nformation ............................................ 69
10.1.4 Publication Policy ........................................................................................ 69
10.1.5 Compliance with Study  Registration and Results Posting Requirements ...70
10.1.6 Compliance with Law, Audit, and Debarment ............................................ 70
10.1.7 Data Qualit y Assurance ............................................................................... 71
10.1.8 Source Documents ....................................................................................... 72
10.1.9 Study  and Site Closure ................................................................................. 72
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 73
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 74
10.3.1 Definition of AE .......................................................................................... 74¬†
¬† 05JCP2
PRODUCT: MK-8591  10
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.3.2 Definition of SAE ........................................................................................ 75
10.3.3 Additional Events Reported ......................................................................... 76
10.3.4 Recording AE and SAE ............................................................................... 76
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................80
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation ....................................82
10.5 Appendix 5: Contraceptive Guidance ................................................................ 83
10.5.1 Definitions ....................................................................................................83
10.5.2 Contraception Requirements ........................................................................84
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 85
10.7 Appen dix 7: Country -specific Requirements .................................................... 90
10.7.1 Country -specific Requirements -German y................................................. 90
10.7.2 Country -specific Requirements ‚ÄìUS.......................................................... 91
10.8 Appendix 8: Blood Volume Table ......................................................................93
10.9 Appendix 9: 12- Lead Electrocardiogram Abnormality Criteri a.................... 94
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values .....96
10.11 Appendix 11: Abbreviations ............................................................................... 97
11 REFERENCES............................................................................................................. 100¬†
¬† 05JCP2
PRODUCT: MK-8591  11
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
LIST OF TABLES
Table 1 Population PK Modeling Projections for ISL Levels After 60 mg. ........... 27
Table 2 Population PK Modeling Projection of I SL Levels After 0.75 mg QD 
Dosing ......................................................................................................29
Table 3 Study  Interventions .................................................................................... 41
Table 4 Allocation of Subjects to Treatment .......................................................... 43
Table 5 Report ing Time Periods and Time Frames for Adverse Events and 
Other Reportable Safet y Events ............................................................... 55
Table 6 Pharmacokinetic (Blood) Collection Windows .........................................59
Table 7 Protocol -required Safet y Laboratory  Assessments ....................................73¬†
¬† 05JCP2
PRODUCT: MK-8591  12
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
LIST OF FIGURES
Figure 1 Study  Design .............................................................................................. 16¬†
¬† 05JCP2
PRODUCT: MK-8591  13
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: An Open -Label, Single -Dose Study  to Evaluate the Pharmacokinetics of 
Islatravir (MK -8591) in Subjects with Severe Renal I mpairment
Short Title: Islatravir ( MK-8591, I SL)Renal Impairment Study  
Acronym: Not applicable 
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with objectives in the O bjectives and Endpoints table.
Primary  Objectives Primary  Endpoints
-To evaluate the plasma pharmacokinetics 
of ISL (e.g., AUC0 -‚àû, AUC0 -last, Cmax, 
Tmax, apparent terminal t¬Ω , CL/F, and 
Vz/F) after a single oral dose of 60 mg ISL 
in subjects with severe renal impairment 
compared to healthy  control subjects.
Estimation: I n subjects with severe renal 
impairment, plasma pharmacokinetics 
(AUC0- ‚àû, Cmax) of I SL following a 
single 60 mg ISL dose will be estimated 
and compared to those observed in healthy  
mean matched control subjects.-AUC0 -‚àû, AUC0 -last, Cmax, Tmax, 
apparent terminal t ¬Ω, CL/F, and Vz/F of 
plasma I SL
Secondary  Objectives Secondary  Endpoints
-To evaluate the safet y and tolerability of 
ISL in subjects with severe renal 
impairment.-Adver se experiences, laboratory  safet y 
tests, ECGs, and VSs.
-To evaluate the intracellular 
pharmacokinetics (e.g., AUC0- ‚àû, AUC0 -
last, Cmax, C24, C168, C672, Tmax, and 
apparent terminal t ¬Ω) of ISL  triphosphate 
(ISL-TP) in peripheral blood mononuclear 
cells (P BMCs) after a single oral dose of 
60 mg ISL in subjects with renal 
impairment compared to healthy  control 
subjects.-AUC0 -‚àû, AUC0 -last, Cmax, C24, C168, 
C672, Tmax, and apparent terminal t ¬Ωof 
ISL-TP in PBMC ¬†
¬† 05JCP2
PRODUCT: MK-8591  14
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Tertiary /Exploratory  Objectives Tertiary /Expl oratory  Endpoints
-To evaluate the plasma pharmacokinetics 
of the metabolite M4 (e.g., AUC0‚àû , 
AUC0 -last, Cmax, Tmax, apparent 
terminal t ¬Ω, CL/F, and Vz/F) after a single 
oral dose of 60 mg ISL in subjects with 
severe renal impairment compared to 
healthy  control subjects.-AUC0 -‚àû, AUC0 -last, Cmax, Tmax, 
apparent terminal t ¬Ω, CL/F, and Vz/F of 
plasma M4
-To explore the relationship between 
genetic variation and response to the 
treatment administered. Variation across 
the human genome will be anal yzed for 
association with clinical data collected in 
this study .-Germline genetic variation
Overall Desig n:
Study  Phase Phase 1
Primary  Purpose Treatment
Indication Treatment of HIV Infection
Population Participants with Severe Renal I mpairment and Healthy  
Participants 
Study  Type Interventional
Intervention Model Single Group
This is a multi- sitestudy .
Type of Control Health y matched control subjects
Study  Blinding Unblinded Open -label
Blinding Roles No Blinding
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately 5months from the time the first participant 
signs the informed consent until the last participant‚Äôs last 
study -related telephone call o r visit.¬†
¬† 05JCP2
PRODUCT: MK-8591  15
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Number of Participant s:
Approximately  12participants will be randomized.
Intervention Groups and Du ration :
Interven -
tion Group sIntervention 
Group Name DrugDose 
StrengthDose 
FrequencyRoute of 
Admin istration Use
Severe Renal 
Impairment 
GroupMK-8591
(ISL)60 mg Single dose Oral Experimental 
Healthy Matched 
Control Group MK-8591
(ISL)60 mg Single dose Oral Experimental 
Total 
Number2
Duration of 
ParticipationEach participant will participate in the study  for approximately  2 months
from the time the participant signs the Informed Consent Form through the 
final contact. 
Study Governance Committees:
Steering Committee No
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Insert Other Oversight Committee No
There are no governance committees in this study .
Study  Accepts Healthy  Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 11.¬†
¬† 05JCP2
PRODUCT: MK-8591  16
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
1.2 Schema
The study  design is depicted in Figure 1. 
Figure 1Study  Design 
¬†
¬† 05JCP2
PRODUCT: MK-8591  17
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
1.3 Schedule of Activities
All P articipants
Intervention Notes
Scheduled Day 1 2 3456 8
Scheduled Hour Screening Pre-
dose00.250.5 1 2 4 6 8 12 24 36 48 72 96 120 168
Administrative /Study Procedures
Informed Consent X
Informed Consent for Future Biomedical 
ResearchX
Participant Identification Card X
Inclusion/Exclusion Criteria X X
Medical History X X
Prior/Concomitant Medication Review X X X-------------------------------------------------------------------- X
Assignment of Screening Number X
Assignment of Treatment Number XSite will follow  local 
SOP for the timing of 
treatment allocation.
Dom iciling X--------------------------------------------------------------------- XRefer to Section 8.1.11
MK-8591 (ISL) Administration X
Safety Procedures
Full physical examination (PE) X XaSymptom -driven PE 
may be performed at 
other times, at the 
Investigator‚Äôs 
discretion.
Height X
Weight X
Vital Signs (heart rate, blood pressure) X X X X Refer to Section 8.3.2
Respiratory Rate X X
Body  Tem perature X X¬†
¬† 05JCP2
PRODUCT: MK-8591  18
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
All P articipants
Intervention Notes
Scheduled Day 1 2 3456 8
Scheduled Hour Screening Pre-
dose00.250.5 1 2 4 6 8 12 24 36 48 72 96 120 168
12-lead ECG X X X X Refer to Section 8.3.3
HIV, hepatitis B and C screen (per site 
SOP)X
Serum /urine Œ≤-Human Chorionic 
Gonadotropin (Œ≤ -hCG)X XRequired for WOCBP.  
Serum or urine Œ≤-hCG 
at predose (per site 
SOP) . Serum Œ≤ -hCG 
required at Screening.
Serum Follicle Stimulating Hormone 
(FSH)XFor WONCBP.
Urine or Blood Drug Screen (UDS/BDS) 
(per site SOP) /alcohol screenX XaAny additional 
UDS/BDS and alcohol 
screen are conducted 
per site SOP.  
Hem atology, urinalysis, and chemistry X XaX X
AE/SAE review X X X--------------------------------------------------------------------- X
Pharm acokinetic s/Biom arkers 
Blood Collection for Plasma ISLin Severe 
Renal Impairment GroupXaX X X X X X X X X X X X X X X
Blood collection for M4 metabolite in 
Severe Renal Impairment GroupXaX X X X X X X X X X X X X X X
Blood for PBMC ISL-TP in Severe Renal 
Impairm ent GroupXaX X X X X
Blood Collection for Plasma ISLin 
Healthy Control GroupXaX X X X X X X X X X X X X X
Blood collection for M4 metabolite in 
Healthy Control GroupXaX X X X X X X X X X X X X X
Blood for PBMC ISL-TPin Healthy 
Control GroupXaX X X X X
Blood for Genetic AnalysisbX¬†
¬† 05JCP2
PRODUCT: MK-8591  19
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
All P articipants
Intervention Notes
Scheduled Day 1 2 3456 8
Scheduled Hour Screening Pre-
dose00.250.5 1 2 4 6 8 12 24 36 48 72 96 120 168
a. Pre-dose PE, urine drug screen, safety labs , and blood sample for plasma ISL/M4 metabolite/PBMC ISL -TPcan be conducted within 24 hours prior to study drug 
administration .  Results from predose safety lab s and drug/alcohol screen must be reviewed prior to treatment allocation.
b. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This sample will not be collected at the site if there is 
either a local law or regulation prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for these purposes. If the sample is collected, leftover 
extracted DNA will be stored for future biomedical research if the participant signs the future biomedical rese arch consent . If the planned genetic analysis is not approved, but 
future biomedical research is approved and consent is given, this sample will be collected for the purpose of future biomedical research .  
*Please refer to Appendix 7 Country Specific Req uirements for screening tests that are applicable to the US only .¬†
¬† 05JCP2
PRODUCT: MK-8591  20
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Intervention Notes 
Scheduled Day 11 15 18 22Post-
trial 
visit/D
ay 29c
Scheduled Hour 240 336 408 504 672
Administrative / Study Procedures
Concomitant Medication Review X X X X X
Safety Procedures
Vital Signs (heart rate, blood pressure) X X X X X Refer to Section 8.3.2
AE/SAE review X X X X X
Hem atology, urinalysis, and chemistry X
Pharm acokinetic s 
Blood for PBMC ISL-TP PK in Severe Renal Impairment 
GroupX X X X X
Blood for PBMC ISL-TP PK in Healthy Control Group X X X X X
c. Post-trial study procedures will be conducted on Day 29 of the study
*Please refer to Appendix 7 Country Specific Requirements for screening tests that are applicable to the US only .¬†
¬† 05JCP2
PRODUCT: MK-8591  21
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
2 INTRODUCTION
Islatravir ( MK-8591, ISL) is a novel, potent NRTTI  being developed both for treatment of 
HIV-1 infection ,and for prevention of HIV- 1 infection in uninfected individuals who are at 
high risk of becoming infected. Currently , ISL is being evaluated in a Phase 2 trial at a dose 
of 0.75 mg QD (in combination with 100 mg doravirine, DOR ; [STUDY_ID_REMOVED]), and in a 
Phase 2 trial at doses of 60 mg and 120 mg QM([STUDY_ID_REMOVED] ).  Additional programs, with 
other doses and administration frequencies within the range of 0.75 -120 mg are being 
consi dered as well. 
2.1 Study Rationale
This Phase 1 study  will evaluate the general tolerability  and pharmacokinetics (PK) of a 
single 60 mg dose of ISLin participants with severe renal insufficiency , compared to 
participants in good health.
2.2 Background
Refer to the IB for detailed background information on ISL.
HIV-1 infection remains a global health challenge, with close to 37 million people living 
with HIV/AIDS worldwide .  The use of ever -improving highly  effective ARVs has greatl y 
improved the natural history  of HIV infection, such that HIV infection has become a chronic 
illness provided patients remain adherent in taking ARV therap y. Globally , almost two 
million people yearly become newl y infected wit h HIV, 
thus demonstrating a need for 
effective prevention strategies that could reduce this infection rate.  There are numerous 
barriers for man y individuals in taking dail y medication, including access t o medication and 
stigma.  Several recent advances in the field, including simplification from 3 -to 2-drug 
regimens and long -acting formulations that potentially  allow for less frequent dosing, are 
attempting to address these needs in order to improve adhe rence and outcomes for patients.
Islatravir is differentiated from other ARVs because of its high potency , long half -life, 
favorable drug resistance profile and broad pharmacological distribution.  Because of these 
properties, ISLis well -suited as a compound to be delivered in less frequent dosing regimens.  
Understanding the effect of intrinsic factors, such as renal insufficiency, on ISLis an 
important aspect of clinical development of the compound.
2.2.1 Pharmaceutical and Therapeutic Background
Islatravir is a highl y potent HIV -1NRT TI.Unlike conventional NRTIs, ISLactsvia 
multiple mechanisms, leading to both immediate and delay ed chain termination.  The 
inactive parent is phosphory lated to the active ISL-TP in PBMCs and other cells.  In in vitro
studies in PBMCs, ISL-TP demonstrated antiviral activity , with an IC 50of 0.21 nM, while 
other NRTIs demonstrated I C50s ranging from 10.1 to 144 nM.  ISLdemonstrates a favorable 
mutant selection profile compared to other NRTIs, selecting onl y for the M184V/I  mutant, 
against which ISLis activ e but with a decrease in sensitivity  of 7.3 -to 9.5-fold.¬†
¬† 05JCP2
352'8&7 0. 
35272&2/$0(1'0(1712 
0. ),1$/35272&2/ -81
7KHHOLPLQDWLRQRI,6/LVDQWLFLSDWHGWRRFFXUE\ERWKH[FUHWLRQ RIXQFKDQJHGSDUHQWGUXJ
DQGPHWDEROLVPYLDDGHQRVLQHGHDPLQDVH$'$WRWKHPDMRUFLUFXO DWLQJ,6/PHWDEROLWH0
¬∂HWK\Q\OIOXRUR ¬∂GHR[\LQRVLQH ,QUDWV,6/ ZDVHOLPLQDWHG SUHGRPLQDQWO\DV0
ZKLOHLQPRQNH\VHOLPLQDWLRQZDVEDODQFHGEHWZHHQ0IRUPDWLRQ DQGUHQDOH[FUHWLRQRI
XQFKDQJHGSDUHQWGUXJ1RPHWDEROLVPRI,6/ZDVREVHUYHGLQKXPD QOLYHUSUHSDUDWLRQVEXW
OLPLWHGWXUQRYHURI,6/YLDGLUHFWJOXFXURQLGDWLRQZDVREVHUY HGLQOLYHUSUHSDUDWLRQVIURP
ERWKUDWVDQGPRQNH\V,VODWUDYLUZDVPHWDEROL]HGLQLQWHVWLQDO SUHSDUDWLRQVDFURVVVSHFLHVWR
0WKHVDPHDVREVHUYHGLQYLYRLQUDWDQGPRQNH\
0H[KLELWV ZHDNDQWLYLUDODF WLYLW\DJDLQVW:7+,9I ROGOHVVSRWHQWWKDQ,6/
SDUHQW0HWDEROLVPYLD$'$LVDQRQF\WRFKURPH3&<3PHGL DWHGSDWKZD\
7KHUHIRUH,6/LVQRWDQWLFLSDWHGWREHDYLFWLPRIGUXJLQWHUDF WLRQV2IQRWH,6/LVDOVRQRW
OLNHO\WRSHUSHWUDWHGUXJLQWHUDFWLRQVDVLWLVQRWDQLQGXFHU RULQKLELWRURIPDMRU&<3
HQ]\PHVRURIPDMRUKHSDWLFDQGUHQDOWUDQVSRUWHUV
,QYLWURVWXGLHVLQPRQNH\DQGKXPDQEORRGLQGLFDWHGWKDW,6/LV HIILFLHQWO\SKRVSKRU\ODWHG
WRWKHPRQRGLDQGWULSKRVSKDWHDQDEROLWHV,6/03,6/'3 DQG,6/73UHVSHFWLYHO\
LQ3%0&V7KHVHSKRVSKRU\ODWHGDQDEROLWHVRI,6/ZHUHQRWGHWHFW HGH[WUDFHOOXODUO\DQGLV
WKHUHIRUHQRWGLUHFWO\H[FUHWHGRUPHWDEROL]HG,6/73 KDVDVL JQLILFDQWO\ORQJHULQWUDFHOOXODU
KDOIOLIHWKDQWKHSDUHQWGUXJWKHLQWUDFHOOXODUKDOIOLIHRI WKHWULSKRVSKDWHDQDEROLWHZDV
GHWHUPLQHGWREHDQGKULQUDWDQGPRQNH\UHVSHFWLYHO\ 3KRVSKRU\ODWHG,6/PD\
EHFRPHGHSKRVSKRU\ODWHGLQ3%0&VDWZKLFKSRLQW,6/PD\WKHQH[ LWWKHFHOODQGUHWXUQWR
WKHSRRORIH[WUDFHOOXODU,6/WKDWLVVXEMHFWWRUHQDOH[FUHWLRQ DQGPHWDEROLVPYLD$'$
 3UHFOLQLFDODQG&OLQLFDO6WXGLHV3RWHQWLDOV\VWHPLFHIIHFWVRI,6/KDYHEHHQH[WHQVLYHO\HYDOXDW HGLQQRQFOLQLFDOVDIHW\
VWXGLHVDVSDUWRIWKHRUDOSURJUDPLQFOXGLQJUHSHDWGRVHRUDO WR[LFLW\DQG3.VWXGLHVLQUDWV
XSWRPRQWKVDQGPRQNH\VXSWRPRQWKV 7KHVHVWXGLHVDUH GHVFULEHGLQGHWDLOLQWKH
0.,6/,% 2YHUDOOWDUJHWRUJDQV\VWHPWR[LFLWLHVLGHQWL ILHGLQHQWHUDOO\
DGPLQLVWHUHG ,6/H[SORUDWRU\DQGRU*/3VWXGLHVLQUDWVDQGPRQN H\VZHUHFRQVLGHUHGQRW
UHOHYDQWDWWKHDQWLFLSDWHGKXPDQ$8&H[SRVXUHIRUDPJGRVH RI,6/EDVHGRQWKHVDIHW\
PDUJLQV¬ï;DWWKH12$(/VRYHUWKHLQWHQGHGFOLQLFDOH[SRVX UHVFRPSDUHGWRWKH
GRVH 

2UDOO\DGPLQLVWHUHG,6/KDVEHHQHYDOXDWHGLQ FRPSOHWHG3KDVH VWXGLHVDQGLVEHLQJ
HYDOXDWHGLQ RQJRLQJ3KDVHVWXG\DQGRQJRLQJ3KDVHVWXGL HV$FURVVWKH 3KDVH
VWXGLHVDVRI6HS DGXOWSDUWLFLSDQWVLQFOXGLQJ SDUWLFLSDQWVZLWK+,9
LQIHFWLRQUHFHLYHGDVLQJOHGRVHXSWRPJ RUDOO\RUPXOWL SOHGRVHVRI,6/XSWR
PJ4:IRUZHHNVDQGXSWRPJ4'IRUZHHNV RUDOO\,QWKH 3KDVHVWXGLHVVLQJOH
DQGPXOWLSOHGRVHVRI,6/KDYHEHHQJHQHUDOO\ZHOOWROHUDWHGZL WK QRGUXJUHODWHG6$(VDQG
QRGLVFRQWLQXDWLRQVGXHWRDGUXJUHODWHG$( )RUDOO3KDVHVW XGLHV ZLWKRUDO
DGPLQLVWUDWLRQWKHPRVWIUHTXHQWO\UHSRUWHGGUXJUHODWHG$(¬ï RISDUWLFLSDQWVLQDQ\
SURWRFROZDVKHDGDFKH
 -&3CCI
PRODUCT: MK-8591  23
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Following oral administration, p lasma PK data indicate that ISLwas rapidly  absorbed with a 
median T maxof 0.5 h r,and an apparent terminal t¬Ω of 47 to 64 hr after single doses. 
Intracellular ISL-TP levels reached C maxbetween 6 to 24 hr and d eclined with an apparent 
terminal t¬Ω of 79 to 214 hr. Over the entire Phase 1 clinical program, ISL plasma exposure 
and I SL-TP levels appeared to increase in an approximately  dose -proportional manner 
between ISL doses of 0.2 5 and 400 mg. M4 levels, when assessed, correspond to ~30 -40% 
of ISL plasma parent levels at all dose levels tested.  Following administration of 30 mg ISL
with a high- fat meal, PKof ISL-TP in PBMCs were largely  unaffected.  Examinations of 
DDIs between ISLand DTG/TDF, ISLand LNG/EE, ISLand DOR, and ISLand 
pantoprazole demonstrated no clinicall y meaningful interactions.
Urine samples were collected for the PK assessment of ISLand to evaluate urinary  excretion 
of intact ISLin healthy  subjects in three P hase I stud ies(P002, P003, P009). Following 
multiple -dose administration with increasing dose from 0.75 mg to 5 mg ISLQD (P009) , 
GM Ae and fe of urine ISLincreased with repeated administration within the 0.75 and 5 mg 
dose levels, whereas GM CL r values appeared similar .Urine fe (fraction excreted) levels 
ranged from 27 -40% at stead y state .
After ISLadminist ration to treatment -na√Øve participants with HIV- 1 infection at doses of 0.5 
mg, 1 mg, 2 mg, 10 mg ,and 30 mg , viral load reduction data show greater than 1.0 log d rop 
on average at all doses tested .Pharmacokinetic data in participants infected with HIV-1 
generall y were consistent with the data in health y participants.
2.2.3 Ongoing Clinical Studies
There are three ongoing studies involving oral ISL.  
Protocol 016 (P016) is a double -blind, placebo- controlled Phase 2 trial (NCT 04003103) in 
low-risk otherwise healthy individuals, examining general tolerability  and PK of QM 
administration of oral I SL alone, to establish greater understanding of potential doses for a 
QM PrEP indication.  This trial is examining doses of 60 mg and 120 mg (and placebo); the 
first subjects were dosed in November 2019.
Protocol 015 (P015) is a multiple panel double -blind placebo- controlled trial in 64 healthy  
adult Japanese males, examining PK an d general safet y and tolerability of ISLup to 30 mg 
and 100 mg DOR.  In P015, which remains blinded, ISL(or placebo) appears to be generally  
well tolerated at all doses examined to date.  
Protocol 011 (P011) is an ongoing Phase 2b trial ([STUDY_ID_REMOVED]) in treatment -naive persons 
living with HIV -1 (PL WH), examining efficacy  of daily  ISL(0.25 mg, 0.75 mg, or 2.25 mg) 
initially  in combination with DOR and 3TC, with 3TC discontinued based on interim 
analysis at 24 weeks, compared to subjects on DOR/3TC/TDF throughout the study  period.  
As of 30 -Sep-2019, ISLhas been administered to ~90 HIV- 1 positive individual s for at least 
48 weeks. The 48 -week analy sis showed a numerically  higher rate of drug-related AEs in 
participants who received DOR/3TC/TDF (19.4%) vs. participants on any dose of ISL(0%, 
10%, 12.9% for 0.25 mg, 0.75mg, and 2.25 mg, respectively ).  Among the 90 participants ¬†
¬† 05JCP2
PRODUCT: MK-8591  24
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
who received an y dose of ISL, there was no specific drug -related AE that occurred in more 
than 5% of the participants.  
Five participants reported 7 SAEs, of which only one was considered drug -related.  This was 
in a subject who received DOR/3TC/TDF (therefore not receiving ISL), who had a 
worsening of congenital long QT s yndrome; this subject withdrew from the study  and the 
event resolved.  Two additional subjects discontinued study medication due to a drug -related 
AE.  Both of these s ubjects initially  received ISL(2.25 mg)/DOR/3TC; one subject 
discontinued because of diarrhea, nausea and vomiting, and the other discontinued due to 
Hepatitis B reactivation.
Of note, enrollment in P011 is open to PL WH with mild renal impairment ( CrCL >50 
mL/min) .  Five individuals receiving ISLhad screening eGFRs ranging from 50 -90 mL /min.  
In exploratory  anal ysisofpotential covariates on PK from P011, CrCL does not appear to be 
a significant covariate .  Given the low number of participants with mild renal insufficiency in 
P011, no conclusions can be drawn yet regarding safet y and tolerability in this population.
2.3 Benefit/Risk Asse ssment
Participants in thisclinical stud ywill not receive direct benefit from treatment during 
participation as clinical s tudies are designed to provide information about the safet y and 
effectiveness of an investigational medicine.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompan ying IBand informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
Objectives Endpoints
Primary
ÔÇ∑To evaluate the plasma pharmacokinetics of 
ISL(e.g., AUC0-‚àû , AUC0 -last, Cmax, 
Tmax, apparent terminal t¬Ω, CL /F, and 
Vz/F) after a single oral dose of 60 mg ISL
in subjects with severe renal impairment 
compared to healthy  control subjects.
Estimation: In subjects with severe renal 
impairment, plasma pharmacokinetics 
(AUC0-‚àû , Cmax) of ISLfollowing a single 
60 mg ISLdose will be estimated and 
compared to those observed in health y mean 
matched control subjects.‚Ä¢AUC0 -‚àû, AUC0 -last, Cmax, Tmax, 
apparent terminal t¬Ω, CL/F, and 
Vz/F of plasma ISL¬†
¬† 05JCP2
PRODUCT: MK-8591  25
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Objectives Endpoints
Secondary
‚Ä¢To evaluate the safet y and tolerability  of ISL
in subjects with severe renal impairment.‚Ä¢Adverse experiences, laboratory  
safet y tests, ECGs, and VS s.
‚Ä¢To evaluate the intracellular 
pharmacokinetics (e.g., AUC0- ‚àû, AUC0 -
last, Cmax, C24, C168, C672, Tmax, and 
apparent terminal t ¬Ω) of ISL triphosphate 
(ISL-TP) in peripheral blood mononuclear 
cells (PBMCs) after a single oral dose of 60 
mg ISL in subjects with renal impairment 
compared to healthy  control subjects.‚Ä¢AUC0 -‚àû, AUC0 -last, Cmax, C24, 
C168, C672, Tmax, and apparent 
terminal t ¬Ωof ISL-TP in PBMC 
Tertiary /Exploratory
‚Ä¢To evaluate the plasma pharmacokinetics of 
the metabolite M4 (e.g., AUC0 ‚àû, AUC0 -
last, Cmax, Tmax, apparent terminal t¬Ω, 
CL/F, and Vz/F) after a single oral dose of 
60 m g ISLin subjects with severe renal 
impairment compared to healthy  control 
subjects.‚Ä¢AUC0 -‚àû, AUC0 -last, Cmax, Tmax, 
apparent terminal t¬Ω, CL/F, and 
Vz/F of plasma M4
‚Ä¢To explore the relationship between genetic 
variation and response to the treatment 
administered. Variation across the human 
genome will be anal yzed for association with 
clinical data collected in this study .‚Ä¢Germline genetic variation
4 S TUDY DESIGN
4.1 Overall Design
This is an open -label, single -dose, multi -sitestudy in subjects with severe renal impairment 
(N=6) and health y mean matched controls (N= 6).  Once all subjects with severe r enal 
impairment are enrolled, the health y matched control subjects will be enrolled. Individual age 
and weight of healthy  matched control subjects will be within the range ¬± 10 y ears and ¬± 10 
kg of the mean age and weight of subjects with severe renal impa irment.   In addition, the 
numbers of males and females of the healthy  subjects will be generall y matched to the 
numbers of renal insufficient subjects within ¬±1.¬†
¬† 05JCP2
PRODUCT: MK-8591  26
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Assignment to a renal function group will be as follows:
Impairment Stage N eGFR (mL/min/1.73 m2)a
Severe 6 < 30, not on dialy sisb
Health y 6 ‚â• 90
aeGFR based on the CKD- EPIequation. Baseline eGFR will be obtained twice (at least 72 hours apart as part of 
subject screening) and the mean of the two values will be used. The second baseline eGFR sample may be 
obtained at the time of check -in.
bReasonable efforts will be made to enroll 1 -2 subjects in the severe renal impairment group who have eGFR 
values of 10 -20 mL/min/1.73 m2.
On Day  1, subjects will receive a single oral dose of 60 mg (6 x 10 mg capsules) ISL, 
followed b y PK sampling until 120 hours postdose (health y control group) or 168hours 
postdose (severe renal impairment group).  There will be additional visits at hours 168, 240, 
336, 408, 504, 672 postd osefor the collection of PBMCs.  Safety  will be monitored 
throughout the stud y by repeated clinical and laboratory evaluations.
Because this is a Phase 1 assessment of ISLin humans, the PK, pharmacody namic, and 
safet y profiles of the compound are still being elucidated. This protocol is therefore written 
with flexibility  to accommodate the inherent d ynamic nature of Pha se 1 clinical studies. 
Refer to Section 8.10 .6for examples of modifications permitted within the protocol 
parameters.
Specific pr ocedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
As the HIV+ popula tion ages, more persons living with HIV (PL WH) will accumulate co -
morbidities, including chronic medical conditions such as diabetes and h ypertension that can 
lead to renal insufficiency.  Existing preclinical and clinical data suggest that renal excretion
of unchanged parent is a major mode of elimination for ISL, and therefore it seems likely that 
individuals with renal insufficiency  may  have higher levels of ISL and perhaps I SL-TP as 
well.  Given the wide dose ranges throughout development noted above (0 .25-400 mg), along 
with favorable preclinical toxicity  studies and an excellent clinical tolerability  profile to date, 
a potential increase in ISL in renall y insufficient subjects is not anticipated to be clinically 
meaningful.
In this trial, PK of ISL in subjects with severe renal insufficiency are being compared to the 
PK in generall y health y study participants.  Confirmation of the expected elevation in I SL 
levels, along with adequate tolerability , in subjects with severe renal insufficiency  would 
suppor t not assessing subjects with mild and moderate renal insufficiency  in this trial.  Based 
on preclinical and clinical PK to date, it is expected that I SL parent levels will increase only 
modestly  (5% for Cmax, ~50% for AUC) in subjects with severe renal insufficiency  relative ¬†
¬† 05JCP2
PRODUCT: MK-8591  27
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
to healthy  study  participants (see Table 1 for levels projected using population PK modeling ), 
while I SL-TP levels will increase as well.  For comparison, the NOAEL from preclinical 
chronic toxicity  studies is 118 ¬µM *hr (0 -168hr), which provides a ~10x exposure margin to 
the levels expected in subjects with severe renal insufficiency .  As noted, doses up to 400 mg 
(which leads to an AUC of 47.1 ¬µM*hr, or a 4x exposure margin) have been generally  well 
tolerated, and to date no dose -related AEs have been observed; thus, a modest increase in I SL 
levels is not likely  to lead to clinically  significant effects .  In addition, an yincrease in I SL-TP 
is not expected to have an adverse effect on efficacy . Such relativel ymodest increases in ISL 
and I SL-TPin subjects with severe renal insufficiency  would suggest that there would be an 
even more modest effect in subjects with mild or moderate renal insufficiency.
Table 1 Population PK M odeling Projections for ISL Levels After 60 mg.
Dose Cmax (¬µM) AUC (¬µM*hr)
60 mg x1 1.01 7.42 (0- inf)
60 mg (severe renal insufficiency ) 1.06 11.19 (0-inf)
4.2.1 Rationale for Endpoints
4.2.1.1 Efficacy Endpoints
No efficacy  endpoints will be evaluated.
4.2.1.2 Safety Endpoints
Multiple trials have evaluated oral ISLin human subjects, including a Phase 1 trial with 
single doses as high as 400 mg and Phase 2 trial in which subjects have received dail y doses 
of up to 2.25 mg ISLfor at least 48 weeks.  To date, oral ISLappears generally  well 
tolerated, and there have been no concerning safety signals from oral ISLadministration.  As 
such, standard safet y monitoring of a dverse events, phy sical examinations, vital signs (heart 
rate and blood pressure), 12 -lead ECGs, and laboratory  tests (hematology , serum chemistry , 
and urinal ysis), obtained pre -and post -dosing, should be adequate to assess tolerability  of 
ISLin this tri al.
4.2.1.3 Pharmacokinetic Endpoints
The primary  endpoints for this study  will include the pharmacokinetic parameters of AUC0 -
‚àû, AUC0 -last, Cmax, Tmax, apparent terminal t¬Ω , CL/F, and Vz/F of plasma ISL.  The
pharmacokinetic parameters AUC0 -‚àû, AUC0 -last, Cmax, C24, C168, C672, Tmax, and 
apparent terminal t¬Ω of ISL-TP in PBMC will be included as secondary  endpoints. These 
parameters correspond to the sy stemic PKof ISLand ISL-TP, respectivel y,following a 
single dose of I SL.  Assessment of these PK parameters for both ISL and ISL -TP has been 
consistently  performed throughout the entire Phase 1 clinical development program.
As ISLis subject to renal clearance, the plasma concentration may  be higher in renal ly
impaired subjects. Plasma PK parameters included in the primary  endpoints will be evaluated¬†
¬† 05JCP2
PRODUCT: MK-8591  28
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
and compared between healthy  and renal lyimpaired subjects , using geometric mean ratio 
(GMR) and confidence interval (CI) to assess differences between the two groups. 
In addition to assessing parent ISL levels, ISL -TP PK parameters will be evaluated as 
secondary  endpoints in healthy  and renal lyimpaired subjects .This will allow a mo re 
complete understanding of I SL-TP levels in this population.  The relationship between ISL 
and I SL-TP levels has been well characterized in healthy  study  participants and in HIV+ 
study  participants.  This assessment, however, will allow greater understan ding of that 
relationship in renall y impaired individuals, and can therefore determine whether ISL -TP 
levels, which are key  to defining the PK threshold for efficacy , will also be sufficient in this 
population.
In addition, PK parameters of M4, the major c irculating metabolite of ISL, will be evaluated 
as exploratory  endpoints in healthy  study  participants and in the renal lyimpaired subjects.  
As with I SL-TP, there is no a priori reason to expect M4 levels to not continue to track at 
~30-40% of ISL levels in plasma in healthy  subjects .  This assessment, however, will allow 
determination of M4 plasma concentrations in renally  insufficient subjects.
4.2.1.4 Pharmacodynamic Endpoints
No pharmacod ynamic endpoints will be evaluated.
4.2.1.5 Planned Exploratory Biomarker Research
4.2.1.5.1 Planned Genetic Analysis
Genetic variation may  impact a participant‚Äôs response to therap y, susceptibility  to, severit y, 
and progression of disease. Variable response to therap y ma y be due to genetic determinants 
that impact drug absorpti on, distribution, metabolism, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and I RB/IEC allow, a sample will be collected for DNA anal ysis 
from co nsenting participants.
DNA samples may be used for research related to the study  intervention( s), the disease under 
study , orrelated diseases. They  may  also be used to develop tests/assay s including diagnostic 
tests related to the disease under stud y, rel ated diseases, and stud y intervention(s). Genetic 
research may  consist of the anal ysis of 1 or more candidate genes , the analy sis of genetic 
markers throughout the genome , or analy sis of the entire genome. Anal ysis may  be 
conducted if it is hy pothesized th at this may  help further understand the clinical data.
The samples may  be analy zed as part of a multi -study  assessment of genetic factors involved 
in the response to understand study  disease or related conditions.
4.2.1.6 Future Biomedical Research
The Sponsor will conduct future biomedical research on DNA spe cimens for which consent 
was pr ovided during this clinical study .¬†
¬† 05JCP2
PRODUCT: MK-8591  29
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and wi ll only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical research is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or th eir therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the correct time. The 
details of future biomedical research are presented in Appendix 6.
4.2.2 Rationale for t he Use of Comparator/Placebo
Not applicable 
4.3 Justification for Dose
A dose of 60 mg h as been selected to be administered as a one -time oral dose in this trial.  As 
noted above, doses of 60 mg and 120 mg are being evaluated in the Phase 2 general 
tolerability  and PK trial.  A dose of 60 mg is being considered for future Phase 3 evaluations 
of QM I SL for pre -exposure proph ylaxis.  As noted, t he PK for both parent ISL and ISL-TP 
has been dose- proportional over the entire dose range evaluated to date (0.25 -400 mg), and 
thus the effects of renal insufficiency are not likely  to vary  with dose.  Based on the 
asses sment of urine e xcretion to date, an increase of ~50% is expected in ISL  plasma levels
in subjects with severe renal insufficiency .  A one -time dose of I SL, as being performed here, 
will be able to inform on other dose administration frequencies, as the PK parameter values 
obtained in this trial can be used to model potential effects .  As shown below ( Table 2 ), the 
expected effect of severe renal insufficiency  after QD dosing would lead to increases in I SL 
levels similar in magnitude to those expected after single dose administration (Table 1 ).
Table 2 Population PK Modeling Projection of I SL Levels After 0.75 mg QD Dosing
Dose Cmax (¬µM) AUC (¬µM*hr)
0.75 mg QD (steady state) 0.013 0.094 (0- 24hr)
0.75 mg QD (steady state, severe renal insufficiency) 0.017 0.146 (0- 24hr)
As this is a Phase 1 assessment of ISLinhumans, and the PK , pharmacod ynamic and safet y 
profiles of the compound are still being evaluated, modifications to the dose or dosing 
regimen may  be required to achieve the scientific goals of the study  objectives and/or to 
ensure appropriate safet y monitoring of the stud y participants. Details of allowed 
modifications are provided in Section 8.10 .6.
4.4 Beginning and End ofStudy Definition
The overall study  begins when the first participant signs the ICF. The overall study  ends 
when the last participant completes the last study -related telephone -call or visit, withdraws 
from the study , or is lost to follow -up (ie, the participant is unable to be contacted b y the 
investigator) .¬†
¬† 05JCP2
PRODUCT: MK-8591  30
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Astudy  may  be paused during review of newl y available preclinical/clinical safet y, PK , 
pharmacod ynamic, efficacy , or biologic data or other items of interest, prior to a final 
decision on continuation or termination of the study. It may  be necessary  to kee p the stud y 
open for gathering/reviewing of additional supportive data to optimally complete the 
objective(s) of the study . If necessary , the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated. If the decision ha s been made to end the 
study  following this review period, the study  end will be defined as the date of the Sponsor 
decision, and this end of study  date supersedes the definitions outlined above . The 
Competent Authority (ies) and IRB(s)/IEC(s) will be appri sed of the maximum duration of 
the study  beyond the last participant out and the justifica tion for keeping the study  open.
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study  early.
5 STUDY PO PULATION
Male/female participants with severe renal impairment between the ages of 18 and 75
(inclusive) andhealthy  matched controls will be enrolled in this study .
The individual age and weight of the health y subjects is aimed to be within the
range ¬±10years and ¬± 10 kg of the mean age and weight of subjects with renal impairment .  
In addition, the numbers of males and females of the health y subjects will be generally 
matched to the numbers of renal insufficient subjects within ¬± 1; i.e., if there are 3 males and 
3 females in the renal insufficient group, every  effort will be made to ensure a 3:3 ratio in the 
healthy  subjects, but 2:4 or 4:2 would be acceptable as well.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
5.1.1 Inclusion Criteria f or Healthy Participants
The following inclusion criteria apply  to all healthy  participants.  Additional inclusion 
criteria that appl y to German y onl y can be found in Appendix 7 Country  Specific 
Requirements.  
Type of Participant and Disease Characteristics 
A participant will be eligible for inclusion in the study  if the participant: 
1. Is in good health based on medical history , physical examination, VS measurements and 
ECGs performed prior to randomization.  Appendix 9 provides a table of the 12- Lead 
Electrocardiogram Abnormality  Criteria.
2.Is in good health based on laboratory  safet y tests obtained at the screening visit and prior 
to study  drug a dministration . Appendix 2 provides a table of laboratory  safety  tests to be ¬†
¬† 05JCP2
PRODUCT: MK-8591  31
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
performed. Appendix 10 provides an algorithm for the assessment of out of range 
laboratory  values.
3.Has a BMI ‚â•18.5 and ‚â§40 kg/m2. See Section 8.3.1 for criteria on rounding to the nearest 
whole number. BMI = weight (kg)/height (m)2.
4.Have a baseline eGFR ‚â• 90mL/min/1.73 m2 based on eGFR equation from CKD -EPIat 
screening:
The CKD -EPI equation is defined as follows:
CKD -EPI Equation:
eGFR = 141 √ó min (S cr/Œ∫, 1)Œ±√ó max(S cr/Œ∫, 1)-1.209√ó 0.993Age√ó 1.018 [if female] √ó 1.159 
[if African American]
Baseline eGFR will be obtained twice (at least 72 hours apart as part of subject
screening), and the mean of the two values will be used. The second baseline eGFR 
sample may  be obtained at the time of check- in.
Participants who have an eGFR of up to 10% below 90 mL /min/1.73m2 may be enrolled 
in the study  at the discretion of the investigator.
Demographics 
5.Ismale or female, from 18 y earsto 75yearsof age inclusive, at the time of signing the 
informed consent.
Male Participants
No measures are needed, but c ontraceptive use b y men should be consistent with local 
regulations regarding the methods of contraception for those participating in clinical studies.
Female Participants
Contraceptive use b y women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.
A female participant is eligible to participate if she is not p regnant or breastfeeding, and at 
least one of the following conditions applies: 
‚Ä¢Is not a WOCBP
OR¬†
¬† 05JCP2
PRODUCT: MK-8591  32
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
‚Ä¢Is a WOCBP and using an acceptable contraceptive method, or be abstinent from 
heterosexual intercourse as their preferred and usual lifesty le (abstinent on a long term 
and persistent basis), as described in Appendix [5] during the intervention period and for 
at least 4 weeks after study  drug administration . The investigator should evaluate the 
potential for contraceptive method failure (ie, noncompliance, rece ntly initiated) in 
relationship to the first dose of study intervention.
‚Ä¢A WOCBP must have a negative highly  sensitive pregnancy  test ([urine or serum] as 
required b y local regulations) within 24 hours before the first dose of study intervention.
‚Ä¢If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy  test is required. I n such cases, the participant must be excluded from 
participation if the serum pregnancy  result is positive.
‚Ä¢Additional requirements for pregnancy  testin g during and after stud y intervention are
located in Appendix [2].
‚Ä¢The investigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  to decrease the risk for inclusion of a woman with an earl y 
undetected pregnancy .
Informed Consent
6.The participant provides written informed consent/assent for the stud y. The participant 
may also provide consent/assent for future biomedical research. However, the participant 
may participate in the main study  without participating in f uture biomedical research
5.1.2 Inclusion Criteria f or Renally Impaired Participants
The following in clusion criteria apply  to all renally  impaired participants.  Additional 
inclusion criteria that apply  to German y only can be found in Appendix 7 Country Specifi c 
Requirements.
A participant will be e ligible for inclusion in the study  if the participant :
Type of Participant and Disease Characteristics
1.With the exception of renal impairment, is in generally good health based on medical 
history , physical examination, VS measurements and ECGs performed prior to 
randomization.  Participants with stable, chronic medical or ps ychiatric conditions, 
including but not limited to hy pertension, hy percholesterolemia, non- insulin dependent 
diabetes mellitus, hy per-or hy pothy roidism, gout, and chronic anxiety  or depression may  
be included at the discretion of the investigator and the Sponsor.  Appendix 9 provides a 
table of the 12 -Lead Electrocardiogram Abnormality  Criter ia. ¬†
¬† 05JCP2
PRODUCT: MK-8591  33
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
2.With the exception of renal impairment, is in good health based on laboratory  safet y tests 
obtained at the screening visit and prior to study  drug administration. Appendix 2 
provides a table of laboratory  safet y tests to be performed. Appendix 10 prov ides an 
algorithm for the assessment of out of range laboratory  values.  
3.Hasa BMI ‚â• 18.5 and ‚â§ 40 kg/m2. See Section 8.3.1 for criteria on rounding to the 
nearest whole number. BMI  = weight (kg)/height (m)2.
4.Have a baseline eGFR < 30 mL/min/1.73 m2 based on eGFR equation from CKD -EPI at 
screening .
The CKD -EPI equation is defined as follows:
CKD -EPI Equation:
eGFR = 141 √ó min (S cr/Œ∫, 1)Œ±√ó max(S cr/Œ∫, 1)-1.209√ó 0.993Age√ó 1.018 [if female] √ó 1.159 
[if African American]
Baseline eGFR will be obtained twice (at least 72 hours apart as part of subject
screening), and the mean of the two values will be used. The second baseline eGFR 
sample may  be obtained at the time of check -in.
Reasonable efforts will be made to enroll an adequate number of sub jects (1 -2subjects) 
in the severe renal impairment group who have eGFR values of 10 -20mL/min/1.73 m2
Demographics
5.Ismale or female , from 18yearsto 75yearsof age inclusive, at the time of signing the 
informed consent.
Male Participants
No measures are needed, but c ontraceptive use b y men should be consistent with local 
regulations regarding the methods of contraception for those participating in clinical studies.
Female Participants
Contraceptive use b y women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least one of the following conditions applies: 
‚Ä¢Is not a WOCBP
OR¬†
¬† 05JCP2
PRODUCT: MK-8591  34
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
‚Ä¢Is a WOCBP and using an acceptable contraceptive method, or be abstinent from 
heterosexual int ercourse as their preferred and usual lifesty le (abstinent on a long term 
and persistent basis), as described in Appendix 5 during the intervention period and for at 
least 4 weeks after the last dose of study  intervention. The investigator should evaluate 
the potential for contraceptive method failure (ie, noncompliance, recentl y initiated) in 
relationship to the first dose of study intervention.
‚Ä¢A WOCBP must have a negative highly  sensitive pregnancy  test ([urine or serum] as 
required b y local regulations) within 24 hours before the first dose of study intervention.
‚Ä¢If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy  test is required. I n such cases, the participant must be excluded from 
participation if the serum pre gnancy  result is positive.
‚Ä¢Additional requirements for pregnancy  testing during and after stud y intervention are 
located in Appendix [2].
‚Ä¢The investigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  to decrea se the risk for inclusion of a woman with an earl y 
undetected pregnancy .
Informed Consent
6. The participant provides written informed consent/assent for the stud y. The 
participant may  also provide consent/assent for future biomedical research. However, 
the participant may  participate in the main study  without participating in future 
biomedical research.
5.2 Exclusion Criteria
5.2.1 Exclusion Criteria f or Heal thy Participants
The following exclusion criteria appl yto all healthy  participants.  Additional exclusion
criteria that apply to the US only  can be found in Appendix 7 Country  Specific 
Requirement s. 
The participant must be excluded from the study  if the participant: 
Medical Conditions 
1.Has a history  of clinically  significant endocrine, gastrointestinal, cardiovascular, 
hematological, hepatic, immunological, renal, respiratory , genitourinary , or major 
neurological (including stroke and chronic seizures) abnormalities or diseases. 
Participants with a remote history  of uncomplicated medical events (eg, uncomplicated 
kidney  stones, as defined as spontaneous passage and no recurrence in the last 5 y ears, or 
childhood asthma) may  be enrolled in the stud y at the discretion of the investigator.¬†
¬† 05JCP2
PRODUCT: MK-8591  35
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
2.Is institutionalized or mentally  or legally  incapaci tated, has significant emotional 
problems at the time of prestudy  (screening) visit or expected during the conduct of the 
study  or has a history  of clinically  significant ps ychiatric disorder of the last 5 years. 
Participants who have had situational depre ssion may  be enrolled in the study  at the 
discretion of the investigator.
3.Has a history  of significant multiple and/or severe allergies (eg, food, drug, latex allergy ), 
or has had an anaph ylactic reaction or significant intolerability  (ie, s ystemic allergi c 
reaction) to prescription or non- prescription drugs or food.
4.Has known h ypersensitivity  to the active substance or an y of the excipients of the study 
drug.
5.Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
6.Had major surgery , donated or lost 1 unit of blood (approximately  500 mL) within 4 
weeks prior to the prestudy  (screening) visit.
Prior/Concomitant Therapy
7.Is unable to refrain from or anticipates the use of any medication, including prescription 
and nonprescription drugs or herbal remedies beginning approximately  2 weeks (or 5 
half-lives) prior to study  drug administration , throughout the stud y,until the poststudy  
visit. There may  be certain medications that are permitted (see Section 6.5).
Prior/Concurrent Clinica l Study Experience
8.Has participated in another investigational study within 4 weeks (or 5 half -lives, 
whichever is greater) prior to the prestud y (screening) visit. The window will be derived 
from the date of the last visit in the previous study.
Diagnosti c Assessments 
9.Has a QTc interval >450 for males or >4 60ms for females, has a history  of risk factors 
for Torsades de Pointes (eg, heart failure/cardiomyopath y or famil y history of long QT 
syndrome), has uncorrected hy pokalemia or h ypomagnesemia, is takin g concomitant 
medications that prolong the QT/QTc interval.
Other Exclusions 
10.Is under the age of legal consent .
11.Is a smoker or user of electronic cigarettes, or has used nicotine or nicotine -containing 
products (eg, nicotine patch) within 3 months of screening.¬†
¬† 05JCP2
PRODUCT: MK-8591  36
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
12.Consumes greater than 1glass of alcoholic beverage or equivalent per day  (12 g/d) for 
females and 2 glasses of alcoholic beverages or equivalent per day (24 g/d) for males
(Note -1 glass is approximately  equivalent to: beer [354 mL /12 ounces], wine [118 mL/4 
ounces], or distilled spirits [29.5 mL /1 ounce]) . Participants who consume more than the 
daily  limit may be enrolled at the discretion of the investigator.
13. Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately  equivalent to 120 mg of caffeine) ,of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day .
14.Is a regular user of cannabis orany illicit drugs or has a history  of drug (inc luding 
alcohol) abuse within approximately  2years. Participants must have a negative drug 
screen prior to randomization.
15.Presents an y concern b y the investigator regarding safe participation in the study  or for 
any other reason the investigator considers the participant inappropriate for participation 
in the study .
16.Is un willing to comply  with the study  restrictions (see Section 5.3 for a complete 
summary  of study  restrictions).
17.Is or has an immediate family  member (eg, spouse, parent/legal guardian, siblin g, or 
child) who is investigational site or Sponsor staff directly involved with this study .
5.2.2 Exclusion Criteria f or Renally Impaired Participants
The following exclusion criteria appl yto all renally  impaired participants.  A dditional 
exclusion criteria t hat appl yto the US only  can be found in Appendix 7 Country  Specific 
Requirements.
The p articipant must be excluded from the study  if the participant:
Medical Conditions
1.Has a history  orpresence of renal artery  stenosis.
2.Has had a renal transplant or nephrectomy .
3.Has rapidl y fluctuating renal function as determined by historical measurements. Rapidly 
fluctuating renal function is defined as > 30% difference between two measurements of 
eGFR taken at least 72 hour apart as part of subject screening.
4.Has ahistory  of an y illness that, in the opinion of the Investigator, might confound the 
results of the study  or poses an additional risk to the subject b y their participation in the 
study .
5.Is institutionalized or mentally  or legally  incapacitat ed at the time of prestudy  (screening) 
visit or expected during the conduct of the stud y.¬†
¬† 05JCP2
PRODUCT: MK-8591  37
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
6.Has a history  of cancer (malignancy ).
Exceptions: (1) A dequately  treated nonmelanomatous skin carcinoma or carcinoma in 
situ of the cervix or ; (2) Other malignancies which have been successfully  treated with 
appropriate follow up and therefore unlikel y to recur for the duration of the study, in the 
opinion of the investigator and with agreement of the Sponsor (eg, malignancies which 
have been successfully  treated ‚â•10 years prior to the prestud y [screening ]visit).
7.Has a history  of significant multiple and/or severe allergies (eg, food, drug, latex allergy ), 
or has had an anaph ylactic reaction or significant intolerability  (ie, s ystemic allergic 
reaction) to prescription or non- prescription drugs or food.
8.Has known h ypersensitivity  to the active substance or an y of the excipients of the study 
drug.
9.Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
10.Had major surgery , donated or lost 1 unit of blood (approximately  500 mL) within 
4weeks prior to the prestudy  (screening) visit.
Prior/Concomitant Therapy
11.Is taking medications to treat chronic medical conditions and/or conditions associated 
with renal disease and has not been on a stable regimen regimen for at least 1 month 
and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 8 
hours after administration of the study  drug.  Exceptions may be granted for subjects in 
whom a medic ation regimen has been adjusted within the three -month window, at the 
discretion of the Investigator and following consultation with the Sponsor .See Section 
5.1.2 for allowed medical conditions, and Section 6.5 for allowed medications. 
Prior/Concurrent C linical Study Experience
12.Has participated in another investigational study within 4 weeks (or 5 half -lives, 
whichever is greater) prior to the prestud y (screening) visit. The window will be derived 
from the date of the last visit in the previous study.
Diagnostic Assessments
13.Has a QTc interval >450for males or >4 60ms for females , has a history  of risk factors 
for Torsades de Pointes (eg, heart failure/cardiomyopath y or famil y history of long QT 
syndrome), has uncorrected hy pokalemia or h ypomagnesemia, is taking concomitant 
medications that prolong the QT/QTc interval.
Other Exclusions
14.Is under the age of legal consent.
15.Does not agree to follow the smoking restrictions as defined b y the CRU.¬†
¬† 05JCP2
PRODUCT: MK-8591  38
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
16.Consumes greater than 1glass of alcoholic beverage or equivalent per day  (12 g/d) for 
females and 2 glasses of alcoholic beverages or equivalent per day (24 g/d) for males
(Note -1 glass is approximately  equivalent to: beer [354 mL /12 ounces], wine [118 mL/4 
ounces], or distilled spirits [29.5 mL /1 ounce]) . Participants who consume more than the 
daily  limit may be enrolled at the discretion of the investigator.
17. Consumes excessive amounts , defined as greater than 6 servings (1 serving is 
approximately  equivalent to 120 mg of caffeine) ,of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day .
18.Is a regular user of cannabis, any  illicit drugs or has a history  of drug (incl uding alcohol) 
abuse within approximately  3 months. Participants must have a negative UDS prior to 
randomization.   Participants with severe renal impairment will be allowed for inclusion 
with a positive UDS for opiates if they  have an active prescription f rom a licensed health 
care provider.
19.Is unwilling to comply  with the study  restrictions (see Section 5.3 for a complete 
summary  of study  restriction s. 
20.Presents an y concern b y the investigator regarding safe participation in the study  or for 
any other reason the investigator considers the participant inappropriate for participation 
in the study .
20.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study .
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
Participants will fast from all food and drinks, except water, for at least 8hours prior to 
laboratory  safet y evaluations and study  drug administration. Participants will fast from all 
food and drinks except water between study  drug administration and the first scheduled meal
which will occur approximately  4 hours after dosing . Thereafter, there will be no restrictions 
(other tha n those provided in Section 5.3.3.) regarding m eals and snack(s). While in the 
CRU, participants will fast from all food and drinks except water between meals and snacks. 
Otherwise, there are no dietary  restrictions other than those defined below.
Water wi ll be provided during stud y drug administration. Water will be restricted 1 hour 
prior to and 1 hour after study  drug administration.
5.3.2 Caffeine, Alcohol ,and Tobacco Restrictions
5.3.2.1 Caffeine Restrictions
Participants will refrain from consumption of caffeinate d beverages or xanthine -containing 
products from 12 hours prior to the prestud y and poststudy visits and from 12 hours prior to 
and after study  drug administration. At all other times, caffeinated beverages or xanthine -¬†
¬† 05JCP2
PRODUCT: MK-8591  39
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
containing products will be limited t o no more than 6 units per day  (1 unit = 120 mg of 
caffeine).
5.3.2.2 Alcohol Restrictions
Participants will refrain from consumption of alcohol 24 hours prior to the prestudy and 
poststudy  visits and from 24 hours prior to and after study  drug administration. At all other 
times, alcohol consumption is limited to no more than approximately  1glass of alcoholic 
beverage or equivalent per day  (12 g/d) for females and 2 glasses of alcoholic beverages or 
equivalent per day  (24 g/d) for males (Note -1 glass is approxim ately  equivalent to: beer 
[354 mL /12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL /1 ounce]) . .
5.3.2.3 Smoking Restrictions
Smoking or the use of electronic cigarettes, or the use of nicotine/nicotine -containing 
products is not permitted for part icipants in the healthy  control group.
Participants in the severe renal impairment group will follow the smoking restrictions (and if 
applicable, the use of electronic cigarettes or nicotine/nicotine -containing products) defined 
by the CRU.
5.3.3 Activity Restrictions
Participants will avoid unaccustomed strenuous phy sical activity  (ie, weight lifting, running, 
bicycling, etc.) from the prestudy  (screening) visit until administration of the initial dose of 
study  drug, throughout the study  and until the poststudy visit.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomized in the study . A minimal set of screen failure information 
may be included, as outlined in the eCRF entry  guidelines. Minimal information may  include 
demograph y, screen failure details, eligibility criteria, and an y AEs or SAEs meeting 
reporting requirements.
5.5 Participant Replacement St rategy
If a participant withdraws from the study a replacement participant may  be enrolled if 
deemed appropriate b y the investigator and Sponsor. The replacement participant will 
generall y receive the same intervention or intervention sequence (as appropriate) as the 
participant being replaced. The replacement participant will be assigned a unique 
treatment/randomization number. The stud y site should contact the Sponsor for the 
replacement participant‚Äôs treatment/randomization number.¬†
¬† 05JCP2
PRODUCT: MK-8591  40
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study  participant according to 
the study  protocol .
Clinical supplie s will be packaged to support enrollment and replacement participants as 
required. When a replacement participant is required, the Sponsor or designee needs to be 
contacted prior to dosing the replacement supplies. Clinical supplies will be affixed with a 
clinical l abel in accordance with regulatory  requirement s.
6.1 Study Intervention(s) Administered
The study intervention (s) to be used in this study isoutlined inTable 3 .¬†
¬† 05JCP2
PRODUCT: MK-8591  41
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Table 3 Study  Intervention s
Arm  Nam eArm  
TypeInter -
vention 
Nam e TypeDose 
Form u-
lationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationRegim en/
Treatm ent 
Period UseIMP/
NIMP Sourcing
Severe 
Renal 
Impair-
ment 
Group Experi -
mentalMK-8591 
(ISL)Drug Capsule 10 mg 60 mg Oral Single 
Dose on 
Day 1Experi -
mentalIMP Provided by 
the Sponsor 
Healthy 
Control 
GroupExperi -
mentalMK-8591
(ISL)Drug Capsule 10 mg 60 mg Oral Single 
Dose on 
Day 1Experi -
mentalIMP Provided by 
the Sponsor 
Definition Investigational Medicinal Product (IMP) and Non -Investigational Medicinal Product (NIMP) is based on guidance issued by the European 
Commission. Regional and/or Country differences of the definition of IMP/NIMP may exist. In these circumstances, local legisl ation is followe d.¬†
¬† 05JCP2
PRODUCT: MK-8591  42
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
All supplies indicated in Table 3 will be provided per the "Sourcing" column depending upon 
local country  operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/bat ch number where possible (eg, not applicable in the 
case where multiple lots or batches may  be required due to the length of the study , etc).
Refer to Section 8.1.8 for details regarding administration of the study  intervention.
6.2 Preparation/Handling/Storag e/Accountability
6.2.1 Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. T he rationale for selection of doses to be used 
in this study  is provided in Section 4. 3.
6.2.2 Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and an y discrepancies are 
reported and resolved before use of the study  intervention.
Only  participants enrolled in the study  may  receive study  intervention, and only  authorized 
site staff may  supply  or administer study  intervention . All study  intervention s must be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicabl e) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
docu mentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locall y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  the Sponsor.
The investigator shall take res ponsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any  applicable laws and regulations .¬†
¬† 05JCP2
PRODUCT: MK-8591  43
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
6.3 Measures to M inimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Subjects will be assigned an allocation number (AN) for a single open- label treatment using 
theallocation schedule shown in Table 4 .
Table 4 Allocation of Subjects to Treatment 
Impairment Stage N Treatment
Severe 6 MK-8591 (ISL)60 mg
Health y 6 MK-8591 (ISL)60 mg
6.3.2 Stratification
No stratification based on age, sex, or other characteristics will be used in this study .
6.3.3 Blinding
This is an open -label study ; therefore, the Sponsor, investigator, and participant will know 
the intervention administered.
6.4 Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply , the preparation of 
the dose will be confirmed by  a second member of the study  site staff.
When participants are dosed at the site, they  will receive stud y intervention directly from the 
investigator or designee, under medica l supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF. 
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a memb er of the stud y site staff other than the person administering the 
study  intervention. Study site personnel will examine each participant‚Äôs mouth to ensure that 
the study  intervention was ingested.
6.5 Concomitant Therapy
If a participant does not discontinue all prior medications within 14 days or 5 half-lives of
the first dose of stud y intervention, he/she may  be included in the study  if the investigator 
can rationalize that the specific use of a prior medication is not clinically relevant within the 
context of the study .
Concurrent use of an y prescription or nonprescription medication, or concurrent vaccination,
during the ongoing stud y (ie, intervention allocation) must first be discussed between the 
investigator and Sponsor prior to administration, unless appropriate medical care necessitates 
that therap y or vaccination should begin before the investigator and Sponsor can consult. The ¬†
¬† 05JCP2
PRODUCT: MK-8591  44
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
participant will be allowed to continue in the study if both the Sponsor and the investigator 
agree.
Paracetamol/acet aminophen may be used for minor ailments without prior consultation with 
the Sponsor.
For Participants with Severe Renal Impairment: 
Participants who are taking medications to treat general medical conditions and/or conditions 
associated with renal disease (e.g., hy pertension, non -insulin dependent diabetes mellitus, 
hypercholesterolemia, h ypo-or hyperthyroidism, gout, depression) will be allowed to 
participate in the stud y at the discretion of the Investigator and following consultation with
the Sponsor Clinical Monitor. Subjects must be on a stable regimen for at least 1 month prior 
to study  drug administration and is able to withhold the use within 4 hours prior to and 8 
hours after stud y drug administration. Any exceptions to this must fi rst be discussed between 
the Investigator and Sponsor. Examples of ty pes of medications that would be allowed 
include (but are not limited to) the following:
ÔÇ∑Angiotensin converting enzy me (ACE) inhibitors, a ngiotensin II receptor antagonists , 
diuretics
ÔÇ∑Beta blockers
ÔÇ∑Metformin, thiazolidinediones, sulfony lureas, DPP -4 inhibitors, alpha -glucosidase 
inhibitors, incretin mimetics
ÔÇ∑Statins
ÔÇ∑Synthroid
ÔÇ∑Colchicine, allopurinol
ÔÇ∑Selective serotonin uptake inhibitors (SSRI s), tricy clic antidepressants
ÔÇ∑Proton pump inhibi tors
Any medication (including over -the-counter) that would significantl y alter eGFR, which, b y 
the determination of the Investigator, might interfere with the study (e.g., cimetidine) must be 
discontinued at least 2 weeks (or 5 half -lives of the compound, whichever is longer) prior to 
the first dosing of stud y drug. 
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study .¬†
¬† 05JCP2
PRODUCT: MK-8591  45
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
6.6 Dose Modification (Escalation/Titration/Other)
Dose modifications are not applicable to this study .
6.6.1 Stopping Rules 
The following stopping rules will be employ ed during the conduct of this study .
If any of the below stopping rules are met, the study will be paused and no further dosing 
will occur until the Sponsor has reviewed the totality  of data available. In order to continue 
the study  (upon joint agreement with the Sponsor and investigator), a namendment will be 
submitted for approval.
1.An individual participant reports a Serious Adverse Event considered related to the study  
drug b y the investigator.
2.Two (2) or more participants report Severe Non -serious Adverse Events considered 
related to the stud y drug by the investigator.
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
This study  is open -label; therefore, the participant, the study  site personnel, the Sponsor, 
and/or designee are not blinded. Study  intervention (name, st rength, or potency ) is included 
in the label text; random code/disclosure envelopes or lists are not provided.
7 DISCONTINUATION OF S TUDY INTERVENTION AND PARTICIPANT 
WITHDRAWAL
7.1 Discontinuation of Study Intervention
In clinical studies with a single intervention, discontinuation of study  intervention can onl y 
occur prior to the intervention and generall y represents withdrawal from the study.
Participants who receive a single -dose intervention cannot discontinue study intervention.
7.2 Participant Withdraw al From the Study
A participant must be withdrawn from the study  if the participant withdraws consent from the 
study .
If a participant withdraws from the study , they  will no longer receive stud y intervention or be 
followed at scheduled protocol visits.¬†
¬† 05JCP2
PRODUCT: MK-8591  46
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific details regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.9. The procedures to be performed should a participan t repeatedl y fail 
to return for scheduled visits and/or if the study  site is unable to contact the participant are 
outlined in Section 7.3.
7.3 Lost t o Follow -up
If a participant fails to return to the clinic for a required study  visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
‚Ä¢The site must attempt to contact the participant and reschedule the missed visit. I f the 
participant is contacted, the participant should be counseled on the importance of 
maint aining the protocol -specified visit schedule.
‚Ä¢The investigator or designee must make every  effort to regain contact with the participant 
at each missed visit (eg, telephone calls and/or a certified letter to the participant‚Äôs last 
known mailing address or locally  equivalent methods). These contact attempts should be 
documented in the participant‚Äôs medical record.
‚Ä¢Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the pa rticipant will be managed via the 
prespecified statistical data handling and anal ysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
‚Ä¢Study  procedures and their timing are summarized in the SoA.
‚Ä¢Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
‚Ä¢The investigator is responsible for ensuring that procedures are conducted by  
appropriatel y qualified (by  education, training, and experience) staff. Delegation of study  
site personne l responsibilities will be docu mented in the I nvestigator Trial File Binder (or 
equivalent).
‚Ä¢All study -related medica l decisions must be made by  an investigator who is a qualified 
physician.
‚Ä¢All screening evaluations must be completed and reviewed to confi rm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
‚Ä¢Procedures conduc ted as part of the participant‚Äôs routine clinical management (eg, blood 
count) and obtained before signing of ICF may be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the ti me frame defined in the SoA.¬†
¬† 05JCP2
PRODUCT: MK-8591  47
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
‚Ä¢Additional evaluations/testing may  be deemed necessary  by the investigator and or the 
Sponsor for reasons related to participant safet y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HI V, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The maximum amount of blood collec ted from each participant over the duration of the study
will not exceed 296.5 mL(Appendix 8).
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant prior to participating in a clinical 
study or future biomedical r esearch .If there are changes to the participant‚Äôs status during the 
study  (eg, health or age of majority  requirements), the investigator or medically  qualified 
designee must ensure the appropriate consent is in place.
8.1.1.1 General Informed Consent
Consent must be docum ented by  the participant‚Äôs dated signature on a consent form along 
with the dated signature of the person conducting the consent discussion.
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the IRB/IEC‚Äôs approval/favorable opinion in advance of use. The 
participant should be informed in a timely  manner if new information be comes available that 
may be relevant to the participant‚Äôs willingness to continue participation in the study . The 
communication of this information will be provided and documented via a revised consent 
form or addendum to the original consent form that captures the participant‚Äôs dated signature.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Spons or requirements.
8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  qualified designee will explain the future biomedical r esearch 
consent to the participant, answer all of his/her questions, and obtain written informed ¬†
¬† 05JCP2
PRODUCT: MK-8591  48
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
consent before performin g any procedure related to future biomedical research. A cop y of the 
informed consent will be given to the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator ,who is a qualified 
physician, to ensure that the participant qualifies for the study .
8.1.3 Participant Identification Ca rd
All participants will be given a participant identification card identify ing them as participants 
in a research stud y. The card will con tain study  site contact information (including direct 
telephone numbers) to be used in the event of an emergency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention randomization,
site personnel will add the treatment /randomization number to the participant identification 
card.
The participant identification card also contains contact information for the emergency  
unblinding call center so that a health care provider can obtain information about study  
intervention in emergency  situations where the investigator is not available.
8.1.4 Medical History
A medical history  will be obtained by  the investigator or qualified designee.
8.1.5 Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qualified designee will review prior medication use, including an y 
protocol -specified washout requirement, and record prior medication taken by the participant 
within 14 day sbefore starting the stud y.
8.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by the participant 
during the stud y.
8.1.6 Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomization . Each participant 
will be assigned onl y 1 screening number. Screening numbers must not be re -used for 
different part icipants.¬†
¬† 05JCP2
PRODUCT: MK-8591  49
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.10.1.
8.1.7 Assignment of Treat ment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
In a situation where rerandomization of the participants is planned (eg, study extension 
periods), the rerandomization will be based on a new randomization schedule; however, each 
participant will retai n his/her original treatment/randomization number. Only  the stud y 
intervention regimen associated with the rerandomization period or phase may change.
8.1.8 Study Intervention Administrati on
Administration of study  intervention(s) will be monitored by the invest igator and/or stud y 
staff.
Participants will fast from all food and drinks, except water, for at least 8 hours prior to study  
drug administration. Participants will remain fasted for 4 hours post dose. Water will be 
provided during study  drug administration but will be restricted 1 hour prior to and 1 hour 
post dose.  
8.1.8.1 Timing of Dose Administration
Participants will be dosed according to the SoA (Section 1.3).
8.1.9 Discontinuation and Withdrawal
The investigator or stud y coordinator must notify the Sponsor when a participant has been 
discontinued/withdrawn from the study . If a participant discontinues for any reason at an y 
time during the course of the study , the participant may  be asked to return to the clinic (or be 
contacted) for a poststudy visit as per the number of day s described in Section 1.3) to have 
the applicable procedures conducted. However, the investigator may  decide to perform the 
poststudy  procedures at the time of discontinuation or as soon as possible after 
discontinuation. I f the poststudy  visit occurs prior to the safet y follow -up time frame as 
specified in Section 8.4.1, the investigator should perform a follow -up telephone call at the 
end of the follow -up period ( Section 8.4.1) to confirm if an y AEs have occurred since the 
poststudy  clinic v isit. Any  AEs that are present at the time of discontinuation/withdrawal 
should be followed in accordance with the safet y requirements outlined in Section 8.4.¬†
¬† 05JCP2
PRODUCT: MK-8591  50
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.1.9.1 Withdrawal From Future Biomedical Resear ch
Participants may  withdraw their consent for future biomedical r esearch. Participants may  
withdraw consent at an y time by  contacting the investigator for the main study . If medical 
records for the main study are still available, the investigator will contact the Sponsor using 
the designated mailbox ( clinical.specimen.management@merck.com). Subsequently ,the 
participant's consent for future biomedical r esearch will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. I t is the responsibility  of the 
investi gator to inform the participant of completion of withdrawal. An y analy ses in progress 
at the time of request for withdrawal or alread y performed prior to the request being received 
by the Sponsor will continue to be used as part of the overall research study  data and results. 
No new analy ses would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the m ain study  records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant‚Äôs personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
8.1.10 Participant Blinding/Unblindi ng
This is an open -label study ; there is no blinding for this study .
8.1.11 Domicili ng
Participants will report to the CRU on Day -1prior to the scheduled day  of study  intervention 
administration on Day  1 and remain in the unit until 120hours p ost dose for health y matched 
controls and 120 hours post dose for participants with severe renal impairment . At the 
discretion of the investigator, participants may be requested to remain in the CRU longer. 
Participants may  be permitted to leave the unit, for emergency  situations only , during the 
domiciling period at the discretion of the investigator after discussion with the Sponsor. The 
decision how to monitor the participant will be at the discretion of the investigator after 
discussion with the Sponsor .  Domiciling of participants will facilitate PK collection and 
safet y assessments while ISL and metabolite levels are expected to be highest, ensuring that 
these assessments are performed in a timel y fashion.
8.1.12 Calibration of Equipme nt
The investigator or q ualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety  or efficacy  parameters shall be suitably
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.¬†
¬† 05JCP2
PRODUCT: MK-8591  51
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.2 Efficacy/Immunogenicity Assessmen ts
There are no direct efficacy  assessments in this study .
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood/tissue to be drawn/collected over the course of the stud y 
(from pre study  to poststudy  visits), including approximate blood/tissue volumes 
drawn/collected by visit and by sample type per particip ant, can be found in Section 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A fullphysical examination will be conducted by an investigator or medically  qualified 
designee (consistent with local requirements) as per institutional standard per SoA. Height 
and weight will also be measured and recorded.
A symptom driven physical examin ation may be performed at other times at the 
Investigator‚Äôs discretion.
BMI
Body Mass Index equals a person's weight in kilograms divided by  height in meters squared 
(BMI=kg/m2). Bod y Mass I ndex will be rounded to the nearest whole number according to 
the standard convention of 0.1 to 0.4 round down and 0.5 to 0.9 round up.
Body weight and height will be obtained with the participant‚Äôs shoes off and jacket or coat 
removed.
8.3.2 Vital Signs
‚Ä¢Body temperature, HR, RR, and BP will be assessed.
‚Ä¢Body temperature will be measured with an appropriate thermometer.
‚Ä¢Blood pressure and pulse measurements will be assessed with a completel y automated 
device. Manual techniques will be used only if an automated device is not available.
‚Ä¢Vital signs will be measur ed in a semi -recumbent position after 10 minutes rest. ¬†
¬† 05JCP2
PRODUCT: MK-8591  52
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.3.2.1 Resting Vital Signs
Vital Sign Measurements (Heart Rate and Blood Pressure)
Participants should be resting in a semirecumbent position for at least 10 minutes prior to 
having VS measurements obtained. Semirecumbent VS will include HR and BP. The correct 
size of the BP cuff and the correct positioning on the participants' arm is essential to increase 
the accuracy  of BP measurements.
Predose HR and BP will be in triplicate measureme nts, obtained at least 1 to 2 minutes apart 
within 3 hours of study  drug administration . The mean of these measurements will be used as 
the baseline to calculate change from baseline for safet y evaluations (and for rechecks, if 
needed). Postdose VS measure ments will be single measurements.
Body Temperature
Body temperature will be measured. The same method must be used for all measurements for 
each individual participant and should be the same for all participants.
8.3.3 Electrocardiograms
‚Ä¢Triplicate and single 12- lead ECG measurements will be obtained and reviewed b y an 
investigator or medicall y qualified designee (consistent with local requirements) as 
outlined in the SoA using an ECG machine that automatically  calculates the HR and 
measures PR, QRS, QT, and QTc intervals. 
‚Ä¢The model of ECG machine will remain consistent for each individual participant.
‚Ä¢Special care must be taken for proper lead placement by  qualified personnel. Skin should 
be clean and dry  prior to lead placement. Participants may  need to be shaved to ensure 
proper lead placement. Female participants may  need to remove interfering garments.
‚Ä¢Participants should be resting in the semirecumbent position for at least 10 minutes prior 
to each ECG measurement.
‚Ä¢The correction formula to be used for QTc is Fridericia.
‚Ä¢If repeat ECGs are required, the clinical site will decide whether to leave the electrodes in 
place or mark the position of the electrodes for subsequent ECGs. To mark the position of 
the electrodes, 12- lead electrode sites will be marked on the skin of each participant with 
an ECG skin marker pen to ensure reproducible electrode placement.
‚Ä¢Predose ECGs will be obtained in triplicate at least 1 -2 minutes apart within 3 hours prior 
to administration of ISL. The mean of these measurements will be used as the baseline to 
calculate change from baseline for safet y evaluations (and for rechecks, if needed). Post -
dose ECG measurements will be single measurements.¬†
¬† 05JCP2
PRODUCT: MK-8591  53
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
‚Ä¢If a participant demonstrates an increase in QTc interval ‚â•60 msec compared with mean 
predose baseline measurement, the ECG will be repeated twice within 5 minutes. The 
mean value of the QTc interval from the 3 ECGs will represent the value at that time 
point. I f the mean QTc interval increase from baseline for an y postdose time point is ‚â•60 
msec, the participant will continue to be monitored by  repeat 12 -lead ECGs every  15 
minutes for at least 1 hour or until the QTc is within 60 msec of baseline. If prolongation 
of the QTc interval ‚â•60 msec persists, a consultation with a study  cardiologist may  be 
appropriate and the Sponsor should be notified.
‚Ä¢If the QTc interval is > 500 msec, the Sponsor should be notified and the ECGs should be 
reviewed b y a cardiologist. The participant should be telemetry -monitored (until the QTc 
is <500 msec) or should be considered for transfer to a location where closer monitoring 
and definitive care (eg, a cardiac or intensive care unit) is available.
‚Ä¢If the participant has unstable hemod ynamics, or has an y clinicall y significant 
dysrhythmias noted on telemetry, the participant should be immediately  transferred to an 
acute care setting for definitive therap y.
‚Ä¢If prolongation of the QTc is noted, concomitant medications that prolong QTc should be 
held until the QTc is within 60 msec of baseline and the QTc is <50 0 msec.
‚Ä¢A study  cardiologist will be consulted b y the investigator as needed to review ECG 
tracings with abnormalities.
8.3.4 Clinical Safety Laboratory Assessments
Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
‚Ä¢The investigator or medically  qualified designee (consistent with local requirements) 
must review the laboratory  report, document this review, and record an y clinically 
relevant changes occurring during the stud y in the AE sec tion of the CRF. The laboratory  
reports must be filed with the source documents. Clinically  significant abnormal 
laboratory  findings are those which are not associated with the underl ying disease, unless 
judged b y the investigator to be more severe than ex pected for the participant's condition.
‚Ä¢All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA .
‚Ä¢If laboratory  values from nonprotocol -specified laboratory  assessments p erformed at the 
institution‚Äôs local laboratory  require a change in study  participant management or are 
considered clinically  significant by  the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).¬†
¬† 05JCP2
PRODUCT: MK-8591  54
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
‚Ä¢For an y laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 14days after study  drug administration , every  attempt 
should be made to perform repeat assessments until the values retur n to normal or 
baseline or if a new baseline is established as determined by  the investigator .
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safet y event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  the participant 
(or, when appropriate, b y a caregiver or surrogate).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety  
events for outcome according to Section 8.4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
AEs, SAEs, and other reportable safety  events that occur after the consent for m is signed but 
before intervention allocation , must be reported by the investigator for randomized 
participants only  if the event is the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usu al therap y, diet, placebo, or a procedure.
From the time of intervention allocation through 28days following cessation of study  drug , 
all AEs, SAEs and other reportable safet y events must be reported b y the investigator.
Additionally , any SAE brought to t he attention of an investigator an y time outside of the time 
period specified in the previous paragraph also must be reported immediately  to the Sponsor 
if the event is considered related to stud y intervention.
Investigators are not obligated to activel y seek AE sor SAEs or other reportable safety  events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in  Table 5 .¬†
¬† 05JCP2
PRODUCT: MK-8591  55
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Table 5 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the Protocol-
specified Follow -up 
PeriodTime Frame to 
Report Event and 
Follow -up 
Information to 
Sponsor:
Nonserious 
Adverse Event 
(NSAE) Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo run -
in or other run -in 
treatmentReport all Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE)Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo run -
in or other run -in 
treatmentReport all Report if:
-drug/vaccine related.
(Follow ongoing to 
outcome)Within 24 hours of 
learning of event
Pregnancy/
Lactation 
ExposureReport if:
-due to intervention
-causes exclusionReport all Previously reported ‚Äì
Follow to 
completion/termination; 
report outcomeWithin 24 hours of 
learning of event
Event of 
Clinical I nterest 
(require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-potential drug -
induced liver injury 
(DILI)
-require regulatory 
reportingNot required Within 24 hours of 
learning of event
Event of 
Clinical Interest 
(do not require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within 5 calendar days 
of learning of event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 calendar days 
of learning of event
Overdose Report if:
-receiving placebo 
run-in or other run- in 
medication Report all Not required Within 24 hours of 
learning of event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safet y events. Open -ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.¬†
¬† 05JCP2
PRODUCT: MK-8591  56
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safet y events ,
including pregnancy  and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in allocated participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safet y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
Sponsor will comply  with country -specific regulatory  requirements and global laws and 
regulations relating to safety  reporting to regulatory authorities, IRB/IECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and Sponsor policy  and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
speci fic safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant ex posure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously  reported to 
the investigator or their designee) that occurs during the stud y are reportable to the Sponsor.
All report ed pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be repor ted as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable.¬†
¬† 05JCP2
PRODUCT: MK-8591  57
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.4.7 Events of Cli nical Interest
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
Events of clinical interest for this study  include: 
1.An overdose of Sponsor's product, as defined in Section 8.5.
2.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by  way  of protocol- specified laboratory  
testing or unscheduled laboratory  testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that must trigger 
an additional evaluation for an underl ying etiology. The study  site guidance for 
assessment and follow up of these criteria can be found in the Investigator Study  File 
Binder (or equivalent).
It may  also be appropri ate to conduct additional evaluation for an underl ying etiology  in the 
setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and alkaline 
phosphatase that do not meet the criteria noted above. In these cases, the decision to proceed 
with additional evaluation will be made through consultation between the study  investigators 
and the Sponsor Clinical Director. However, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for this study.
8.5 Treatment of Overdose
For purposes of this study, an overdose will be defined as an y dose of an y drug administered 
as part of the stud y exceeding the dose prescribed by  the protocol. It is up to the investigator 
or the reporting ph ysician to decide whether a dose is to be considered an overdose, in 
consultation with the Sponsor.
8.6 Pharmacokinetics
The decision as to which plasma samples collected will be assay ed for evaluation of PK will 
be collaborativel y determined by  the Sponsor (eg, samples at lower doses may  not be assay ed 
if samples at higher doses reveal undetectable drug concentrations). If indicated, these 
samples may  also be assay ed and/or pooled for assay  in an exploratory  manner for 
metabolites and/or additional pharmacod ynamic markers .
8.6.1 Bloo d Collection for Plasma ISL and PBMC ISL-TP
Blood collection time points for plasma ISLandPBMC ISL-TP are outlined in the SoA 
(Section 1.3).  Sample collection, storage, and shipment instructions for plasma samples will 
be provided in the study operations manual.¬†
¬† 05JCP2
PRODUCT: MK-8591  58
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Biomarke rs
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from all participants as 
specified in the SoA:
‚Ä¢Blood for Genetic Analysis 
8.8.1 Planned Genetic Analysis Sample Collection
The p lanned genetic a nalysis sample should be drawn for planned analy sis of the association 
between genetic variants in DNA and drug response. This sample will not be collected at the 
site if there is either a local law o r regulation prohibiting collection, or if the I RB/IEC does 
not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored for future biomedical researc h if the participant signs 
the future bi omedical r esearch consent. If the planned genetic analysis is not approved, but 
future biomedical r esearch is approved and consent is given, this sample will b e collected for 
the purpose of future biomedical r esearch.
Sample collection, storage, and shipment instruct ion for planned genetic analysis samples 
will be provided in the operations/laboratory manual.
8.9 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
‚Ä¢Leftover DNA for future research
8.10 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details areprovided 
inSection 8.
8.10.1 Screening
Approximately  3weeks prior to intervention randomization, potential participants will be 
evaluated to determine that they  fulfill the entry  requirements as set forth in Section 5.
Participants may  be rescreened after consultation with the Sponsor. Rescreening should 
include all screening procedures listed in the SoA, including consent review. Rescreen 
procedures cannot be conducted the day  prior to intervention randomization if there are Day  -
1 procedures planned per protocol.¬†
¬† 05JCP2
PRODUCT: MK-8591  59
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
8.10.2 Treatment Period
Refer to the Schedule of Activities (Section 1.3).
8.10.3 Discontinued Participants Continuing to be Monitored in the Study
At any  point if a participant discontinues from treatment but continues to be monitored in the 
study , allofthestudy  procedures specified in the SoA may  be completed at the discretion of 
the investigator and with Sponsor agreement. The subset of study  procedures completed will 
be communicated in a PCL .
8.10.4 Posts tudy
Poststudy  procedures will be conducted on Day  29 of the study .  
8.10.5 Critical Procedures Based on Study Objectives: Timing of Procedu re
For this study , the blood sample for ISLis the critical procedure.
At any  postdose time point, the blood sample for ISLneeds to be collected as close to the 
exact time point as possible. All other procedures should be completed as close to the 
prescri bed/scheduled time as possible. Study  procedures can be performed prior or after the 
prescribed/scheduled time.
The order of priorit y can be changed during the study  with joint agreement of the investigator 
and the Sponsor Clinical Director.
Any nonschedul ed procedures required for urgent evaluation of safet y concerns take 
precedence over all routine scheduled procedures.
The following variance in procedure collection times will be permitted.
‚Ä¢PK Collection as outlined in Table 6 .
Table 6 Pharmacokinetic (Blood) Collection Windows
PK Collection PK Collection Window
0 -<1 hr 5 min
1 -<24 hr 15 min
24-<48hr 1 hr
48- ‚â§120 hr 2 hr
120 ‚Äì 168 hr 6 hr
ÀÉ168 hr 24 hr¬†
¬† 05JCP2
PRODUCT: MK-8591  60
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
‚Ä¢Predose standard safet y evaluations: vital signs and ECG up to 3 hrs; laboratory safet y 
tests and phy sical exam up to 24 hrs
‚Ä¢Postdose standard safet y evaluations : vital signs, ECG, laboratory  safet y tests, and
physical exam
-<24 hr postdose may  be obtained within 15 min of the theoretical sampling time
-24 hr - <48 hr postdose may  be obtained within 1 hr of the theoretical sampling time
-48 hr ‚Äì ‚â§120 hr postdose may  be obtained within 2 hr of the theoretical sampl ing time
-120 ‚Äì 168 hr postdose may be obtained within 6 hr of the theoretical sampling time
-> 168 hr postdose may  be obtained within 24 hr of the theoretical sampling time
8.10.6 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase 1 assessment of ISLin humans, and the PK, pharmacod ynamic, and safet y 
profiles of the compound arestill being elucidated. This protocol is written with some 
flexibility  to accommodate the inherent d ynamic nature of Phase 1 clinical studies.
Modifications to the dose, dosing regimen, and/or clinical or laboratory  procedures currently  
outlined may  be required to achieve the scientific goals of the study  objectives and/or to 
ensure appropriate safet y monitoring of the stud y participants.
As suc h, some alterations from the currentl y outlined dose and/or dosing regimen may be 
permitted based on newly available data, but the maximum daily  dose may  not exceed those 
currentl y outlined in the protocol.
‚Ä¢Decrease in the dose of the study  intervention ad ministered 
‚Ä¢Modification of the PK sample processing and shipping details based on newly  available 
data
The PK sampling scheme currently  outlined in the protocol may  be modified during the study  
based on newl y available PK or pharmacod ynamic data (eg, to obtain data closer to the time 
of peak plasma concentrations). If indicated, these collected samples may  also be assay ed in 
an exploratory  manner for metabolites and/or additional pharmacod ynamic markers.
Up to additional 50 mL  of blood may  be drawn for saf ety, PK, and/or pharmacod ynamic 
analyses. The total blood volume withdrawn from any single participant will not exceed the 
maximum allowable volume during his/her participation in the entire study (Appendix 8).
The timing of procedures for assessment of sa fety procedures (eg, vital signs, ECG, safet y 
laboratory  tests, etc.) may  be modified during the study  based on newl y available data. 
Additional laboratory  safety  tests may  be added to blood samples previously  drawn to obtain ¬†
¬† 05JCP2
PRODUCT: MK-8591  61
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
additional safet y information. These changes will not increase the number of study 
procedures for a given participant during his/her participation in the entire study .
It is understood that the current stud y ma y emplo y some or none of the alterations described 
above. An y alteration mad e to this protocol to meet the study  objectives must be detailed b y 
the Sponsor in a letter to the Study  File and forwarded to the investigator for retention. The 
letter may  be forwarded to the I RB/IEC at the discretion of the investigator .
9 STATISTICAL ANALYSIS PLAN
9.1 Statistical Analysis Plan Summary
This section contains a summary  of the statistical anal yses for this trial. Full detail is in the 
Statistical Methods (Section 9.6).
Safety: The safet y and tolerability  of ISLwill be evaluated b y clinical assessment of adverse 
events and other safet y measurements. Summary  statistics for the laboratory  safet y tests, 
ECGs, and/or vital signs may also be computed and provided, as deemed clinically  
appropriate.
Pharmacokinetic s: Separatel y for each P K parameter and anal yte, individual values of
plasma ISLAUC0 -‚àû, AUC0 -last, Cmax , CL/F, and Vz/F , PBMC IS L-TP AUC0 -‚àû, AUC0 -last, 
Cmax, C24, C168, C672 , plasma M4 AUC0 -‚àû, AUC0 -last, Cmax , CL/F, and Vz/F after a single 
dose administration of 60 mg ISLto subjects with severe renal impairment and healthy
subjects will be natural log -transformed and evaluated with a linear fixed effects model
containing a categorical effect for population ( subjects with severe renal impairment, health y 
subjects).  An unstructured covariance matrix will be used to allow for unequal population 
variances via the REPEATED and GROUP statement in SAS PROC MI XED.  Kenward and 
Roger's method will be used to calculate the denominator degrees of freedom for the fixed 
effect (DDFM=KR).  Ninety -five percent (95%) confidence intervals for the least squares 
means for each population will be constructed on the natural log scale and will reference the 
t-distribution. Exponentiating the least- squares means and their corresponding 95% 
confidence limits will y ield estimates for the population geometric means and confidence 
intervals about the geometric means on the original scale.  To address the primary  estimation 
objective and compare subjects with severe renal impairment to subjects with normal renal 
function , a two-sided 90% confidence interval for the true difference in means ( subjects with 
severe renal impairment ‚Äìhealthy  subjects) will be calculated for each PK parameter using 
the mean square error from the model and referencing a t -distribution.  These confidence 
limits will be exponentiated to obtain the 90% confidence interval for the true ratio of 
geometric means ( subjects with severe renal impairment/healthy  subjects) for each PK 
parameter .  
Sample Size and Power Calculations: The between- subject standard deviations (on the 
natural log scale) for plasma ISLAUC0 -‚àû and Cmax, PBMC MK -8951- TP AUC0- ‚àû and 
Cmax after administration of ISLobserved in a previous study  (PN003 ) are 0.228, 0.356, 
0.414 and 0.518, respectively . Assuming the same variability for 60- mg ISL, with 6 severe 
renal impairment subjects and 6 health y subjects , the half width of the 90% confidence ¬†
¬† 05JCP2
PRODUCT: MK-8591  62
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
intervals of geometric mean ratios (GMR)s for plasma ISLAUC0 -‚àû and Cmax,  PBMC MK -
8951- TP AUC0- ‚àû and Cmax on the log scale will be 0.239, 0.372, 0.443, and 0.542
respectivel y. The lower and upper 90% confidence limits for the true GMRs will be given b y 
OBS/1.2 7and OBS*1.27 for plasma ISLAUC0 -‚àû, OBS/1. 45, and OB S*1.45for plasma ISL
Cmax, OBS/1. 54and OBS*1.54 for AUC0 -‚àû ISL-TP in PBMC, OBS/1.72, and OBS*1. 72
for Cmax ISL-TP in PBMC , where OBS is the observed least squares geometric mean . 
9.2 Responsibility for Analyses
The statistical anal ysis of the data obtained from this study  will be conducted by , or under the 
direct auspices of, the Early  Clinical Development Statistics Department in collaboration 
with the Quantitative Pharmacology  and Pharmacometrics Department and Translational 
Pharmacology  Departmen t of the Sponsor.
If, after the stud y has begun, changes are made to the statistical anal ysis plan stated below, 
then these deviations to the plan will be listed, along with an explanation as to why they 
occurred, in the Clinical Study  Report.
9.3 Hypotheses/Estimation
Estimation: I n subjects with severe renal impairment, plasma pharmacokinetics (AUC0 -‚àû, 
Cmax) of ISLfollowing a single 60 mg ISLdose will be estimated and compared to those 
observed in healthy  mean matched control subjects.
9.4 Analysis Endpoints
Primary  Endpoints
The primary  PKendpoints include plasma ISLAUC0 -‚àû, AUC0 -last, Cmax, Tmax, apparent 
terminal t¬Ω, CL/F, and Vz/F. 
Secondary  Endpoints 
The secondary  PK endpoints include AUC0 -‚àû, AUC0 -last, Cmax, C24, C168, C672, Tmax, 
and appa rent terminal t ¬Ω of ISL-TP in PBMC . The secondary  safet y endpoints include 
adverse experiences, laboratory  safet y tests, ECGs, and VSs. 
Exploratory  Endpoints: 
The exploratory endpoints include AUC0 -‚àû, AUC0 -last, Cmax, Tmax, apparent terminal t¬Ω, 
CL/F, and Vz/F of M4 in plasma. The exploratory endpoints also include genetic variation 
and response to the treatment administered. ¬†
¬† 05JCP2
PRODUCT: MK-8591  63
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
9.5 Analysis Populations
The following populations are defined for the analy sis and reporting of data. All participant s 
willbe reported, and their data analy zed, according to the treatment(s) they actuall y received.
All Subjects as Treated (ASaT): The All Subjects as Treated Population consists of all
participant s who received at least one dose of treatment. This population will be used for
assessments of safety  and tolerability .
Per-Protocol (PP): The Per -Protocol Population consists of the subset of participant s who 
comply  with the protocol sufficiently  to ensure that generated data will be likely  to exhibit 
the effects of treatment, according to the underly ing scientific model. Compliance covers 
such considerations as exposure to treatment, availability  ofmeasurements and absence of 
important protocol deviations. Important protocol deviations will be identified to the extent 
possible prior to unblinding b y individuals responsible for data collection/compliance, and its 
analysis and interpret ation. Any  participant s or data val uesexcluded from analy sis will be 
identified, along w ith their reason for exclusion, in the CSR. At the end of the study, all 
participant s who are compliant with the study  procedure as aforementioned and have 
available data considered sufficient to exhibit the effect of treatment will be included in the
Per-Protocol dataset. This population will be used for the PK analyses.
9.6 Statistical Methods
No value for AUC0 -‚àû, apparent terminal t ¬Ω, CL /F, or Vz/F will be reported for cases that do 
not exhibit a terminal log -linear phase in the concentration versus time profile. 
Pharmacokinetic s: Separatel y for each PK parameter and anal yte, individual values of
plasma ISLAUC0 -‚àû, AUC0 -last, Cmax , CL/F, and Vz/F , PBMC IS L-TP AUC0 -‚àû, AUC0 -last, 
Cmax, C24, C168, C672 , plasma M4 AUC0 -‚àû, AUC0 -last, Cmax , CL/F, and Vz/F after a single 
dose administration of 60 mg ISLto subjects with severe renal impairment and healthy
subjects will be natural log -transformed and evaluated with a linear fixed effects model
containing a categorical effect for population ( subjects with severe renal impairment, health y 
subjects).  An unstructured covariance matrix wil l be used to allow for unequal population 
variances via the REPEATED and GROUP statement in SAS PROC MI XED.  Kenward and 
Roger's method will be used to calculate the denominator degrees of freedom for the fixed 
effect (DDFM=KR).  Ninety -five percent (95%) confidence intervals for the least squares 
means for each population will be constructed on the natural log scale and will reference the 
t-distribution. Exponentiating the least- squares means and their corresponding 95% 
confidence limits will y ield estima tes for the population geometric means and confidence 
intervals about the geometric means on the original scale.  Sample SAS code is given below:
proc mixed data=data;
   class population ;
   model lnpk = population /ddfm=kr;
   repeated/ group= populatio n type=UN;
   lsmeans population /cl alpha=0.05; 
run;¬†
¬† 05JCP2
PRODUCT: MK-8591  64
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
To address the primary  estimation objective and compare subjects with severe renal 
impairment to subjects with normal renal function, a two-sided 90% confidence interval for 
the true difference in mean s (subjects with severe renal impairment ‚Äìhealthy  subjects ) will 
be calculated for each PK parameter using the mean square error from the model and 
referencing a t -distribution.  These confidence limits will be exponentiated to obtain the 90% 
confidence i nterval for the true ratio of geometric means (subjects with severe renal 
impairment/healthy  subjects) for each PK parameter .  
Individual values will be listed for each PK parameter (plasma ISLAUC0 -‚àû, AUC0 -last, 
Cmax, Tmax, apparent terminal t¬Ω, CL/F, and Vz/F , PBMC ISL-TP AUC0 -‚àû, AUC0 -last, 
Cmax, C24, C168, C672, Tmax, and apparent terminal t ¬Ω, plasma M4 AUC0--‚àû , AUC0 -
last, Cmax, Tmax, apparent terminal t¬Ω, CL /F, and Vz/F )by population, and the following 
(non-model -based) descriptive statistics will be provided: N (number of subjects with non -
missing data), arithmetic mean, standard deviation, arithmetic  percent CV (calculated as 100 
x standard deviation/arithmetic mean), median, minimum, maximum, geometric mean, and 
geometric percent CV (calcul ated as  100 x sqrt(exp(s2) -1), where s2is the observed 
variance on the natural log -scale).
Figures showing individual PK values with GMs (95% CI s) by population, plotted on the 
natural log scale, will be provided for ISLplasma AUC0 -‚àû, AUC0 -lastand C max. Individual 
subject PK values will also be plotted against BSA normalized eGFR and against BSA un -
normalized eGFR , using different s ymbols to identify  subjects from each population. For this 
analysis, eGFR will be calculated as the mean of the two values determined at screening.  
Plots of PK parameters versus CLcrusing the C-G equation will also be provided.  
Additi onally , plots of PK parameter value svs age and body  mass index (BMI) may be 
provided . 
Summary  Statistics using BSA un- normalized eGFR   The subjects will be re -categorized into 
different renal categories based on their BSA un -normalized eGFR and non -model based 
summary  statistics by  population will be provided for plasma ISLAUC0 -‚àû, AUC0 -last, Cmax , 
CL/F, and Vz/F , PBMC IS L-TP AUC0 -‚àû, A UC0- last, Cmax, C24, C168, C672, plasma M4 
AUC0 -‚àû, AUC0 -last, Cmax , CL/F, and Vz/F .
Analy sis usi ng CLcr (C -G equation) :  The subjects will be re -categorized into different renal 
categories based on their CL cr obtained from C -G equation and non- model based summary  
statistics by  population will be provided for plasma ISLAUC0 -‚àû, AUC0 -last, Cmax, CL/F, and 
Vz/F, PBMC IS L-TP AUC0 -‚àû, AUC0 -last, Cmax, C24, C168, C672, plasma M4 AUC0 -‚àû, 
AUC0 -last, Cmax, CL/F, and Vz/F. 
Safety: The safet y and tolerability  of ISLwill be evaluated b y clinical assessment of adverse 
events and other safet y measurements. Summary  statistics for the laboratory  safet y tests, 
ECGs, and/or vital signs may also be computed and provided, as deemed clinically  
appropriate.¬†
¬† 05JCP2
PRODUCT: MK-8591  65
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
9.7 Interim Analyses
Not applicable. 
9.8 Multiplicity
There is nopre-specified hy pothesis ; therefore, no multiplicity  adjustment is needed.
9.9 Sample Size and Power Calculations
The between- subject standard deviations (on the natural log scale) for plasma ISLAUC0 -‚àû 
and Cmax, PBMC MK -8951- TP AUC0- ‚àû and Cmax after administration of ISLobserved in 
a previous stud y (PN003) are 0.228 ln(hr* nmol/L) , 0.356 ln(nmol/L) , 0.414 ln(hr* pmol/10^6 
Cells) and 0.518 ln(pmol/10^6 Cells) , respectivel y. Assuming the same variability  for 60- mg 
ISL, with 6 severe renal impairment subjects and 6healthy  subjects, the half width of the 
90% confidence interval s of geometric mean ratios (GMR)s for plasma ISLAUC0 -‚àû and 
Cmax, PBMC MK -8951- TP AUC0- ‚àû and Cmax on the log scale will be 0.239, 0.372, 0.443, 
and 0.542 respectivel y. The lower and upper 90% confidence limits for the true GMRs will 
be given b y OBS/1.2 7and OBS*1.2 7 for plasma ISLAUC0 -‚àû, OBS/1. 45, and OBS*1.45 for 
plasma ISLCmax, OBS /1.54and OBS*1.54 for AUC0 -‚àû ISL-TP in PBMC, OBS/1.72, and 
OBS*1. 72for Cmax ISL-TP in PBMC , where OBS is the observed least squares geometric 
mean . ¬†
¬† 05JCP2
PRODUCT: MK-8591  66
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10 SUPPORTING DOCUMENTATION AND OP ERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducte d 
in compliance with local and/or national regulations (including all applicable data protection regulations), and 
International Council for Harmonisation Good Clinical Practice (ICH -GCP), and also in accordance with the 
ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials, which are not u nder the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical pow er) must be adequate to address the specific 
purpose of the trial. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants , adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by MSD personnel (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per MSD policies and procedures, if fraud, ¬†
¬† 05JCP2
PRODUCT: MK-8591  67
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
scientific/research misconduct or serious GCP -non-compliance is suspected, the issues are investigated. 
When necessary, the clini cal site will be closed, the responsible regulatory authorities and ethics review 
committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather 
than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD‚Äôs policy on authorship is consistent with the recommendations published by the International Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protectio n
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by MSD for regulatory authority 
acceptance/authorization prior to implementa tion of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form, investigator‚Äôs brochure, and other relevant trial 
documents must be reviewed and approved by an IRB/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval.  
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to the m.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or individuals acting on behalf of MSD), ethics committee, and/or regulatory 
author ities will have access to confidential medical records that might identify the participant by name.
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics committee.¬†
¬† 05JCP2
PRODUCT: MK-8591  68
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is MSD‚Äôs policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does n ot pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by MSD, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commit ment
Investigators will be expected to review MSD‚Äôs Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further ag ree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided b y 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the Unite d States for these purposes. This may  involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
The Sponsor will conduct this study  in compliance with all applicable data protection 
regulations.¬†
¬† 05JCP2
PRODUCT: MK-8591  69
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Participants will be assigned a unique identifier by the Sponsor. An y participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant mus t be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authori zed personnel appointed by  the S ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities.
10.1.3.1 Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affili ated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by the investigator, except to the e xtent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2 Confidentiality of Participant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF data. By  signing the consent form, the participant agrees to this 
process. If study  documents will be photocopied during the process of verify ing 
worksheet /CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connect ion with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study . The Sponsor is al so required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
10.1.4 Publication Policy
The results of this study  may  be published or presented at scientific meetings. The Sponsor 
will comply  with the requirements for publication of study  results. I n accordance with ¬†
¬† 05JCP2
PRODUCT: MK-8591  70
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
standard editorial and ethical practice, the Sponsor will generall y support publication of 
multicenter studies only  in their entiret y and not as individual site data. I n this case, a 
coordinating investigator will be designated b y mutual agreement.
If publication activity  is not directed b y the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary  inform ation and to provide comments.
Authorship will be determined by  mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements .
10.1.5 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the st udy is solely  responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate stud ies for their 
disease conditions and pursue participation b y calling a central contact number for further 
information on appropriate study  locations and study  site contact information.
By signing this protocol, the investigator acknowledges that the statut ory obligations under 
FDAAA, the EMA clinical trials directive ,or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this study  or its results to those 
registries.
10.1.6 Compliance with Law, Audit, and Debar ment
By signing this protocol, the investigator agrees to conduct the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of GCP
(eg, International C ouncil on Harmoni sation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generall y accepted 
standards of GCP ); and all applicable federal, state and local laws, rules and regulations 
relating to the conduct of the clinical study .
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored b y MSD, is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .¬†
¬† 05JCP2
PRODUCT: MK-8591  71
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations re sulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsor‚Äôs studies. The investigator 
will immediately  disclose in writing to the Sponsor if an y person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator‚Äôs knowledge, threatened .
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically  (eg, labor atory  data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct b y 
physicall y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for inspection, 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or an y regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conduct ed in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investig ator for 15 y ears after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during ¬†
¬† 05JCP2
PRODUCT: MK-8591  72
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
the retention period without the written approval of the Sponsor. No records may  be 
transferre d to another location or part y without written notification to the Sponsor .
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. The investigator/institution should ma intain adequate and 
accurate source documents and study  records that include al lpertinent observations on each 
of the site‚Äôs participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Change s to source data should be 
traceable, should not obscure the original entry , and should be explained if necessary  (eg, via 
an audit trail). Source documents are filed at the investigator‚Äôs site.
Data reported on the CRF or entered in the eCRF that are tran scribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study . Also, current medical records must be available .
10.1.9 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GC P.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor or 
designee will promptly  notify  that study  site‚Äôs IRB/IEC as specified b y applicable regulatory 
requirement(s).¬†
¬† 05JCP2
PRODUCT: MK-8591  73
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.2 Appendix 2: Clinical Laboratory Tests
‚Ä¢The tests detailed in Table 7will be performed b y the local laboratory .
‚Ä¢Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Secti on 5 of the protocol.
‚Ä¢Additional tests may  be performed at an y time during the study as determined necessary 
by the investigator or required by  local regulations.
Table 7 Protocol -require d Safet yLaboratory  Assessments
Laboratory 
Asse ssmentsParameters
Hem atology Platelet Count RBC Indices:
MCV
MCH
%ReticulocytesWBC count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hem oglobin
Hem atocrit
Chemistry Blood Urea Nitrogen 
(BUN)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -Oxaloacetic 
Transaminase (SGOT)Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
elevated above the 
upper limit of 
normal)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase (SGPT)Total Protein
Glucose (fasting ) Calcium Alkaline phosphatase
Magnesium 
Routine 
Urinalysis‚Ä¢Specific gravity
‚Ä¢pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, leukocyte 
esterase] by dipstick
‚Ä¢Microscopic examination (if blood or protein is abnormal)
Other Screening 
Tests‚Ä¢Follicle -stimulating hormone (as needed in women of nonchildbearing potential only)
‚Ä¢Serum or urine alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opiates, cannabinoids and benzodiazepines) .  Alcohol breath 
test for alcohol screen is permitted . 
‚Ä¢Serum or urine Œ≤ human chorionic gonadotropin (Œ≤ hCG) pregnancy test (a s needed 
for WOCBP)
‚Ä¢Serology [(HIV antibody, hepatitis B surface antigen [HBsAg], and hepatitis C virus 
antibody)]
*Please refer to Appendix 7 Country Specific Requirements for screening tests that are 
applicable to the US only .
NOTES:   Laboratory safety tests will be performed after at least an 8 -hour fast. Pre-dose Day 1 laboratory 
procedures can be conducted up to 24 hours prior t o study drug administration.
The i nvestigator (or medically  qualified designee) must document their review of each 
laboratory  safet y report.¬†
¬† 05JCP2
PRODUCT: MK-8591  74
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
ÔÇ∑An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study intervention.
ÔÇ∑NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
ÔÇ∑NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor‚Äôs 
product) includes an y pharmaceutical product, biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo , active comparator product, or run -in intervention) , manufactured by , licensed 
by, provided by , or distributed by  the Sponsor for human use in this study .
Events meeting the AE definition
ÔÇ∑Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the medical 
and scientific judgment of the investigator.
ÔÇ∑Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
ÔÇ∑New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
ÔÇ∑Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
ÔÇ∑Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
ÔÇ∑For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  ‚Äúaccidental or intentional overdose without adverse effect.‚Äù
‚Ä¢Any new cancer or progression of existing cancer.¬†
¬† 05JCP2
PRODUCT: MK-8591  75
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Events NOT meeting the AE d efinition
¬∑Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
ÔÇ∑Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
ÔÇ∑Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
ÔÇ∑Surgery  planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
ÔÇ∑Refe r to Section 8.4.6 for protocol -specific exceptions.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
‚Ä¢The term ‚Äú life-threatening ‚Äùin the definition of ‚Äúserious‚Äù refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing h ospitalization
‚Ä¢Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a precautionary  measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre -existing condition that has not 
worsened is not an SAE. )A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant‚Äôs 
medical history .
d.Results in persistent or significant disability/i ncapacity
‚Ä¢The term disability  means a substantial disruption of a person‚Äôs ability  to conduct 
normal life functions.¬†
¬† 05JCP2
PRODUCT: MK-8591  76
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
‚Ä¢This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
‚Ä¢In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
‚Ä¢Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be i mmediately  life-threatening or result in death or hospitalization but may  
jeopardize the participant or may require medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events should usually  be 
considere d serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependenc y 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
‚Ä¢Is a cancer
‚Ä¢Is associa ted with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
ÔÇ∑When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory , and diagnostics reports) related to 
the event.
ÔÇ∑The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
¬∑It is not acceptable for the investigator to send photocopies of the participant‚Äôs medical 
records to the Sponsor in lieu of completion of the AE CRF page.¬†
¬† 05JCP2
PRODUCT: MK-8591  77
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
ÔÇ∑There may  be instances when copies of medical records for certain cases are requested b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copies of the medical records before submission to the 
Sponsor.
ÔÇ∑The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as th e AE/SAE.
Assessment of i ntensity /toxicity
ÔÇ∑An event is defined as ‚Äúserious‚Äù when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
‚Ä¢The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) by  recording the grade according to the NIH DAIDS Table for 
Grading the Severity  of Adult and Pediatric Adverse Events, version 2.1. Any  AE which 
changes DAIDS grade over the course of a given episode will have each change of grade 
recorded on the AE CRFs/worksheets.
-Grade 1 Mild event : Mild sy mptoms causing no or minimal interference with usual 
social and functional activities with intervention not indicated.
-Grade 2 Moderate event : Moderate s ymptoms causing greater than minimal 
interference with usual social and functional activities with intervention indicated.
-Grade 3 Severe event: Severe s ymptoms causing inability  to perform usual social and 
functional activities with intervention or hospitalization indicated.
-Grade 4 Potentiall y life -threatening event: Potentially  life-threatening s ymptoms 
causing inability  to perform basic self -care funtions with intervention indicated to 
prevent permanent impa irment, persistent disability , or death.
-Grade 5 Death: Deaths related to an AE.
Assessment of c ausality
‚Ä¢Did the Sponsor ‚Äôs product cause the AE?
‚Ä¢The determination of the likelihood that the Sponsor ‚Äôs product caused the AE will be 
provided b y an investigator who is a qualified ph ysician. The investigator‚Äôs signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initialed 
document must be retained for the required regulatory  time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available in formation.¬†
¬† 05JCP2
PRODUCT: MK-8591  78
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
‚Ä¢The following components are to be used to assess the relationship between the 
Sponsor ‚Äôs product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ‚Äôs 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ‚Äôs product such as: reliable history , acceptable compliance assessment (pill 
count, diary , etc.), expected pharmacologic effect, or measurement of 
drug/metabolite in bodil y specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ‚Äôs product? I s the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal 
product)?
-Likely Cause: Is the AE not reasonabl y explained by  another etiology  such as 
underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor ‚Äôs product discontinued or dose/exposure/fre quency  
reduced?
‚ó¶If yes, did the AE resolve or improve?
‚ó¶If yes, this is a positive dechallenge.
‚ó¶If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability ; (2) the AE resolved/impr oved despite continuation of the Sponsor ‚Äôs 
product; (3) the stud y is a single -dose drug stud y; or (4) Sponsor ‚Äôs product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor ‚Äôs product in this study ?
‚ó¶If yes, did the AE recur or worsen?
‚ó¶If yes, this is a positive rechallenge.
‚ó¶If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability , or (2) the study  is a single -dose drug study ; or (3) Sponsor ‚Äôs 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR ‚ÄôS PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR ‚ÄôS PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PAR TICIPANT THEN THE RECHALLENGE MUST BE APPROVED I N ¬†
¬† 05JCP2
PRODUCT: MK-8591  79
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
ADVANCE BY THE SPONSOR CLINI CAL  DIRECTOR, AND IF REQUI RED, THE 
IRB/IEC .
‚Ä¢Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge re garding the Sponsor ‚Äôs product or drug class 
pharmacology  or toxicology ?
‚Ä¢The assessment of relationship will be reported on the case report forms/worksheets b y 
an investigator who is a qualified phy sician according to his/her best clinical judgment, 
includi ng consideration of the above elements.
‚Ä¢Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ‚Äôs product relationship).
-Yes, there is a reasonable possibility  of Sponso r‚Äôs product relationship:
‚ó¶There is evidence of exposure to the Sponsor ‚Äôs product. The temporal sequence 
of the AE onset relative to the administration of the Sponsor ‚Äôs product is 
reasonable. The AE is more likely  explained by  the Sponsor ‚Äôs product than by  
another caus e.
-No, there is not a re asonable possibility  of Sponsor‚Äô s product relationship:
‚ó¶Participant did not receive the Sponsor ‚Äôs product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ‚Äôs product is not reasonable 
OR the AE is more l ikely explained by  another cause than the Sponsor‚Äôs 
product. (Also entered for a participant with overdose without an associated 
AE.)
‚Ä¢For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
‚Ä¢There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
‚Ä¢The investigator may change his/her opinion of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality  assessment.
‚Ä¢Thecausality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.¬†
¬† 05JCP2
PRODUCT: MK-8591  80
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Follow -up of AE and SAE
ÔÇ∑The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by  Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care pro fessionals.
ÔÇ∑New or updated information will be recorded in the CRF.
ÔÇ∑The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety e vent reporting to Sponsor via electronic d ata 
collection t ool
ÔÇ∑The primary  mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic s ystem is unavailable for more than 24 hours, then the site will 
use the paper AE Reporting form.
‚ó¶Reference Section 8.4.1 for reporting time requirements.
ÔÇ∑The site will enter the SAE data into the electronic system as soon as it becomes 
available.
ÔÇ∑After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
ÔÇ∑If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by telephone (see next section).
ÔÇ∑Contacts for SAE reporting can be found in the Investigator Study  File Binder (or 
equivalent).¬†
¬† 05JCP2
PRODUCT: MK-8591  81
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
SAE reporting to the Sponsor via paper CRF
¬∑If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
ÔÇ∑In rar e circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
ÔÇ∑Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
ÔÇ∑Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent) .¬†
¬† 05JCP2
PRODUCT: MK-8591  82
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not applicable. ¬†
¬† 05JCP2
PRODUCT: MK-8591  83
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below):
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study  interve ntion, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
‚Ä¢Premenarchal
‚Ä¢Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpingectomy
-Documented bilateral oophor ectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come fr om the site personnel‚Äôs review of the participant‚Äôs 
medical records, medical examination, or medical history  interview.
‚Ä¢Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
‚ó¶A high FSH leve l in the postmenopausal range may  be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of 12 months of amenorrhea, confirmation with two 
FSH measurements in the postmenopausal range is required .
-Females on HRT and whose menopausal status is in doubt will be required to use one 
of the nonhormonal highly effective contraception methods if they wish to continue 
their HRT during the study . Otherwise, they  must discontinue HRT to allow 
confirmation o f postmenopausal status before study  enrollment.¬†
¬† 05JCP2
PRODUCT: MK-8591  84
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
‚Ä¢Progestogen -only contraceptive implantc,d
‚Ä¢IUSc,e
‚Ä¢Non-hormonal IUD
‚Ä¢Bilateral tubal occlusion
‚Ä¢Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the p artner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoosp ermia can come from the site personnel‚Äôs revie w of the participant‚Äôs 
medical records, medical examination, or medical history intervie w.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly.
‚Ä¢Com bined (estrogen -and progestogen -containing) hormonal contraceptionc,d
-Oral
-Intravaginal
-Transdermal
-Injectable
‚Ä¢Progestogen -only hormonal contraceptionc,d
-Oral
-Injectable
Sexual Abstinence
‚Ä¢Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the stu dy and the preferred and usual lifestyle 
of the participant.
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
‚Ä¢Progesterone -only hormonal contraception where inhibition of ovulation is not the primary mode of action
‚Ä¢Male or female condom with or without spermicide
‚Ä¢Cervical cap, diaphragm, or sponge with spermicide
‚Ä¢A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double 
barrier methods)f
aContraceptiv e use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for participants of clinical studies.
bTypical use failure rates are higher than perfect -use failure rates (ie, when used consistently and correctly ).
cMale condoms must be used in addition to hormonal contraception.
dIf locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to 
those which inhibit ovulation.
eIUS is a progestin releasing IUD.
fA combination of male condom with either cap, diaphragm, or sponge with spermicide are considered 
acceptable, but not highly effective, birth control methods.
Note: The follow ing are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, post -ovulation methods), w ithdrawal (coitus 
interruptus), spermicides only, and LAM.
-  Male and female condom should not be used together (due to risk of failure with friction ).¬†
¬† 05JCP2
PRODUCT: MK-8591  85
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1. Definitions
a. Biomarker: A biological molecule found in blood, other bod y fluids, or tissues 
that is a sign of a normal or abnormal process or of a condition or disease. A 
biomarker may be used to see how well the body  responds to a treatment for a 
disease or condition.1
b. Pharmacogenomics: The investigation of variations of DNA and RNA 
characteristics as related to drug/vaccine response.2
c. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the 
influence of variations in DNA sequence on drug/vaccine response.2
d. DNA: Deox yribonucleic acid.
e. RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 9will 
be used in various experiments to understand:
‚ó¶The biology  of how drugs/vaccines work
‚ó¶Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
‚ó¶Other pathway s with which drugs/vaccines may  interact
‚ó¶The biol ogy of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understandi ng of how 
individuals respond to drugs/vaccines, enhance our understanding of human disease 
and ultimately  improve public health through development of novel treatments 
targeted to populations with the greatest need. All specimens will be used by the 
Sponsor or those working for or with the Sponsor.
3. Summary of Procedures for Future Biomedical Research.
a. Participants for Enrollment¬†
¬† 05JCP2
PRODUCT: MK-8591  86
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
All participants enrolled in the clinical study  will be considered for enrollment in 
future biomedical research.
b. Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, 
at a study  visit by  the investigator or his or her d esignate. Informed consent for 
future biomedical r esearch should be presented to the participants on the visit 
designated in the SoA. If delay ed, present consent at next possible Participant 
Visit. Consent forms signed by the participant will be kept at the clinical study 
site unde r secure storage for regulatory  reasons.
A template of each stud y site‚Äôs approved informed consent will be stored in the 
Sponsor‚Äôs clinical document repository .
c. eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical r esearch will be 
captured in the eCRFs . Any  specimens for which such an informed consent 
cannot be verified will be destroy ed.
d. Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as 
outlined in the SoA. I n general, if additional blood specimens ar e being collected 
for future biomedical r esearch, these will usually  be obtained at a time when the 
participant is having blood drawn for other stud y purposes.
4. Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. 
In fac t little or no research can be conducted without connecting the clinical study  data 
to the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history  and intervention outcomes 
are critical to understanding clinical context of analy tical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be singl e-coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded with in it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers 
will appear on the specimen tube.¬†
¬† 05JCP2
PRODUCT: MK-8591  87
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
5. Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be 
performed b y the Sponsor, or an additional third party (eg, a universit y investigator) 
designated b y the Sponsor. The investigator conducting the analysis will follow the 
Sponsor‚Äôs privacy  and confidentiality  requirements. Any  contracted third party  anal yses 
will conform to the specific scope o f anal ysis outlined in future biomedical research 
protocol and consent . Future biomedical r esearch specimens remaining with the third 
party  after specific anal ysis is performed will be reported to the Sponsor.
6. Withdrawal From Future Biomedical Research
Participants may  withdraw their consent for future biomedical r esearch and ask that 
their biospecimens not be used for future biomedical r esearch. Participants may  
withdraw consent at an y time by  contacting the investigator for the main study . If 
medical records for the main study  are still available, the investigator will contact the 
Sponsor using the designat ed mailbox (clinical.specimen.management@merck.com). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only . If specimens were collected from study participants 
specificall y for future biomedica l research, these specimens will be removed from the 
biorepository  and destro yed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsibility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if 
the investigator is no longer required b y regulatory authorit ies to retain the main study  
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant‚Äôs personal information and their specimens. In this 
situation, the request for withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to 20 y ears from the end of the main study . Specimens may  be stored for 
longer if a regulatory  or governmental authorit y has active questions that are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the study  site will be shipped to a central laboratory  and then shipped 
to the Sponsor -designated biorepository . If a central laboratory is not utilized in a 
particular stud y, the study site will ship directl y to the Sponsor -designated 
biorepository . The specimens will be stored under strict supervision in a limited ac cess ¬†
¬† 05JCP2
PRODUCT: MK-8591  88
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
facility  which operates to assure the integrit y of the specimens. Specimens will be 
destroy ed according to Sponsor policies and procedures and this destruction will be 
documented in the biorepository  database.
8. Data Security
Databases containing spe cimen information and test results are accessible only  to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using networ k securit y policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may  publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and participants. Participants will not be 
identified by  name in any published reports about this study  or in any  other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies f or future biomedical r esearch.
11. Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biomedical r esearch informed consent.
The Sponsor has develo ped strict securit y, policies, and procedures to address 
participant data privacy  concerns. Data privacy  risks are largel y limited to rare 
situations involving possible breach of confidentiality . In this highl y unlikely situation, 
there is risk that the in
formation, like all medical information, may  be misused.
12. Questions
Any questions related to the future biomedical research should be e mailed directly  to 
clinical.specimen.management@merck.com.¬†
¬† 05JCP2
PRODUCT: MK-8591  89
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
13. References
1. National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618
2. International Council on Harmoni sation [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -
single/article/definitions -for-genomic -biomarkers- pharmacogenomics -
pharmacogenetics -genomic -data-and-sample -cod.html 
3. Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide 
for IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
4. Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/¬†
¬† 05JCP2
PRODUCT: MK-8591  90
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.7 Appendix 7: Country -specific Requirements
10.7.1 Country -specific Requirements -Germany
The following specif ies‚Äúgood health‚Äù with respect to t heinclusion criteria.
Section 5.1.1 I nclusion Criteria for Health y Participants 
Inclusion criteri on#1:
‚ÄúIs in good health based on medical history , physical examination , VS measurements and 
ECGs performed prior to randomization. Appendix 9 provides a table of the 12 -Lead 
Electrocardiogram Abnormality  Criteria ‚Äù
In this Inclusion Criterion, with respect to blood pressure ,‚Äúgood health‚Äù is defined as systolic 
blood pressure notmore than 139 mm Hg and the diastolic blood pressure notmore than 89 
mmHg.
Inclusion criteri on#2: 
‚ÄúIs in good health based on laboratory safet y tests obtained at the screening visit and prior to 
study  drug administration. Appendix 2 provides a table of laboratory safety  tests to be 
performed. Appendix 10 provides an algorithm for the assessment of out of range laboratory  
values .‚Äù
In this Inclusion Criterion, w ith respect to specific laboratory results, ‚Äúgood health‚Äù is 
defined so that ALT, AST, and b ilirubin values (except if consistent with Gilbert‚Äôs disease)
should not exceed the upper limit of normal ( ULN ); any other abnormal laboratory
parameters must be considered not clinicall y significant .
Section 5.1.2 Inclusion C riteria for Renally  Impaired Participants
Inclusion criteri on#1:
‚ÄúWith the exception of renal impairment, is in generall y good health based on medical 
history , physical examination , VS measurements and ECGs performed prior to 
randomization .  Participants with stable, chronic medical or ps ychiatric conditions, including 
but not limited to hy pertension, hy percholesterolemia, non -insulin dependent diabetes 
mellitus, hy per-or hy pothy roidism, gout, and chronic anxiety  or depression may  be included 
at the discretion of the investigator and the Sponsor.  Appendix 9 provides a t able of the 12-
Lead Electrocardiogram Abnormality  Criteria. ‚Äù
In this Inclusion Criterion, with respect to blood pressure, ‚Äúgood health‚Äù is defined as systolic 
blood pressure not more than 160 mm Hg and diastolic blood pressure not more than 100 mm
Hg.¬†
¬† 05JCP2
PRODUCT: MK-8591  91
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Inclusion criteri on#2:
‚ÄúWith the exception of renal impairment, is in good health based on laboratory  safet y tests 
obtained at the screening visit and prior to study  drug administration. Appendix 2 provides a 
table of laboratory  safety tests to be performe d.Appendix 10 provides an algorithm for the 
assessment of out of range laboratory  values. ‚Äù
In this Inclusion Criterion, w ith respect to specific laboratory results, ‚Äúgood health‚Äù is 
defined so that onlyclinically  significant lab abnormalities associated with renal disease are 
accept able; any other abnormal laboratory parameters must be considered not clinically  
significant for inclusion .
10.7.2 Country -specific Requirements ‚ÄìUS
Section 1.3 Schedule of Activities 
The following safet y procedures are applicable to the United States ( US)only.  Please refer 
to Section 1.3 Schedule Activities for other safety procedures required for all participants.
Participants in the US only 
Intervention Notes
Scheduled Day 1 2 3456 8
Scheduled Hour Screening Pre-
dose00.250.51 2 4 6 8 12 24 36 48 72 96 120 168
Safety Procedures
HIV, hepatitis B and C 
screen . HIV -2 
included for the US 
onlyX
GC/CT (gonorrhea + 
chlamydia) screen ‚Äì
US onlyXPer site 
SOP 
Syphilis serologic 
screening ‚ÄìUS onlyXPer site 
SOP
Trichomonas testing ‚Äì
US onlyXIf 
available, 
per site 
SOP 
Intervention Notes 
Scheduled Day 11 15 18 22Post-trial 
visit/Day 
29c
Scheduled Hour 240 336 408 504 672
Safety Procedures
HIV Screen (including HIV -2) ‚ÄìUS only X
c. Post- trial study procedures will be conducted on Day 29 of the study .¬†
¬† 05JCP2
PRODUCT: MK-8591  92
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Section 5.2 Exclusion Criteria 
The following exclusion criteria apply  to healthy  and renall y impaired participants in the US 
only.  Please refer to Section 5.2 Exclusion Criteria for other exclusion cr iteria required for 
all participants. 
1. Is not considered low risk of having HIV infection. L ow risk for HIV infection is 
defined b y all of the following, within 12 months prior to the screening visit (based 
on self -report by  participant or medical history  [if available]):
a.No anal or vaginal intercourse with someone known to be HIV -infected, or with 
someone of unknown HIV infection status who is at increased risk of HIV 
infection.
b.No stimulant use (cocaine [including crack], methamphetamine, or nonph ysician 
prescribed pharmaceutical grade stimulants) or inhaled nitrous oxide.
c.No illicit injection drug use of an y kind.
d.No new diagnosis of a sexually  transmitted infection (STI) such as gonorrhea 
(GC), chlam ydia (CT), incident sy philis, or trichomoniasis (if assessment is 
available). This includes, but is not exclusive to, any testing performed at 
screening.
e.No greater than 3 different sexual partners for receptive or insertive vaginal or 
anal sex; and
f.No history  of antiretroviral therap y for HIV -1 infect ion, including for PrEP or for 
post-exposure prophy laxis. Note: individuals who have participated in studies of 
an antiretroviral, including Phase 1 studies, may be eligible after Sponsor 
consultation.
Section 10. 2 Clinical L aboratory  Tests 
The following Clinical Laboratory  Tests are applicable to the US onl y.  Please refer to 
Appendix 2 Clinical Laboratory  Tests for other screening tests required for all participants.
Other Screening 
Tests‚Ä¢HIV-2 included in HIV screen at screening and HIV screen (HIV -1/HIV-2) 
on Day 29 ‚ÄìUS only
‚Ä¢Syphilis serologic testing -US only
‚Ä¢GC/CT testing per site SOP -US only
‚Ä¢Trichomonas testing, if available , per site SOP ‚ÄìUS only¬†
¬† 05JCP2
PRODUCT: MK-8591  93
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.8 Appendix 8: Blood Volume Table
All Participants Pre-study Treat ment Periods Post-studyTotal 
CollectionsmL Per 
CollectionTotal mL/ 
Test
Laboratory Safety Tests (all 
subjects; includes FSH if 
applicable, Œ≤- hCG if 
applicable, and 
HIV/Hepatitis screen)2 2 1 5 17 85c
Blood for Genetic Analysis 1 0 0 1 8.5 8.5
Blood for PBMC ISL-TP 0 11 0 11 16 176
Blood for Plasma ISL 1 14-15b0 15-16 4 60 ‚Äì64
Blood for plasma M4 1 14-15b0 15-16 3 45-48
Total Blood Volume per participant: 374.5 to 
381.5 mL
aIf additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood (up to 50mL) 
may be obtained. Note: never to exceed 50 mL.
bDuring the treatment period, 15 blood collections for plasma ISL and M4 in healthy control group and 16 blood 
collections for plasma ISL and M4 in severe renal impaired group.
c.Total blood volume for laboratory safety tests (including screening tests) throughout the study, but may be a lower
volume based on site‚Äôs SOP .  Additionally, H IV screen will include HIV -2 in the US only , syphilis serologic testing 
will be conducted in the US only , and an HIV screen will be conducted on Day 29 in the US only .  Please refer to 
Appendix 7 Country Specific Requirements.¬†
¬† 05JCP2
PRODUCT: MK-8591  94
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.9 Appendix 9: 12-Lead Electrocardiogram Abnormality Criteria
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure Criteria Potentially Significant 
Post-randomization Findings 
(clarification on action to take)
RHYTHM
Sinus TachycardiaÔÄæ110 bpm for renally impaired 
participants 
>90 bpm for healthy participantsHR >110 bpm for renally impaired 
participants and >90 bpm for 
healthy participants
ANDHR increase of ‚â•25bpm 
from baseline
Sinus Bradycardia <50 bpmHR < 50 bpm and HR decrease of 
‚â•5bpm from baseline
Sinus Pause/Arrest >2.0 seconds >2.0 seconds
Atrial Premature C omplex ÔÄæÔÄ†1 beat ÔÇ≥ÔÄ†3 beats
Ventricular Prema ture C omplex All ÔÇ≥ÔÄ†3 beats
Ectopic Atrial Rhythm None None
Junctional RhythmJunctional Rhythm with HR < 40 
bpmJunctional Rhythm with HR < 40 
bpm
Idioventricular Rhythm All All
Atrial Fibrillation All All
Atrial Flutter All All
Supraventricular Tachycardia All All
Ventricular Tachycardia All All
AXIS
Left Axis DeviationRBBB W ith Left Anterior 
Hem iblock (LAHB)New  Onset LAHB
Right Axis DeviationRBBB W ith Left Posterior 
Hem iblock (LPHB)New  Onset LPHB
CONDUCTION
1st Degree A V Block PR ÔÇ≥ 230 msPR ÔÇ≥ÔÄ† 230 ms   + Increase of ÔÄæ15 
ms; or PR Increase of > 25%
2nd Degree AV Block Mobitz Type II Mobitz Type II
3rd Degree A V Block All All
LBBB All All
RBBBRBBB With LAHB/LPHB as 
Defined A boveNew  Onset RBBB (N ot Including 
Rate-related)
Incomplete Right BBB (ICRBBB) 
(QRS <120 ms)No E xclusion Nothing
Short PR/ Preexcitation S yndrome Delta W ave + PR <120 ms Delta W ave + PR <120 ms
Other Intra -Ventricular 
Conduction DelayQRS ÔÇ≥130 msQRS ÔÇ≥130 ms + I ncrease of ÔÇ≥10 
ms
QTc F
Male QTc ÔÇ≥450msQTc ÔÇ≥500 ms or I ncrease of ÔÇ≥60 
ms From B aseline
Female QTc ÔÇ≥460msQTc ÔÇ≥500 ms or I ncrease of ÔÇ≥60 
ms From B aseline¬†
¬† 05JCP2
PRODUCT: MK-8591  95
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure Criteria Potentially Significant 
Post-randomization Findings 
(clarification on action to take)
HYPERTROPHY
Atrial AbnormalitiesDefinite Evidence of P Mitrale or 
P Pulmo naleDefinite Evidence of P Mitrale or 
P Pulmo nale
Ventricular A bnormalitiesVoltage Criteria for LVH P lus 
Strain PatternVoltage Criteria  for LVH P lus 
Strain Pattern
MYOCARDIAL INFARCTION
Acute or Recent All All
Old All All
ST/T MORPHOLOGY
ST Elevation S uggestive of 
Myocardial Injury In 2 or more contiguous leads In 2 or more contiguous leads
ST Depression S uggestive of
Myocardial Ischaemia In 2 or more contiguous leads In 2 or more contiguous leads
T-wave Inversions Suggestive of 
Myocardial Ischaemia In 2 or more contiguous leads In 2 or more contiguous leads
Non-specific ST -T Changes 
(In 2 or More L eads)No exclusion In 2 or more contiguous leads
PACEMAKER All All
Baseline is defined as Predose Day 1 ; ms=milliseconds, mm=millimeter¬†
¬† 05JCP2
PRODUCT: MK-8591  96
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory  values obtained at prestud y (screening) visit and/or predose evaluation:
A.If all protocol -specified laboratory  values are normal, the participant may  enter the stud y.
B.If a protocol specified laboratory  value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study .
C.If ‚â•1 protocol -specified laboratory  value not specified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
1. The participant may  be excluded from the study ;
2. The participant may  be included in the study  if the abnormal value(s) is NCS 
(the investigator must annotate the laboratory  value ‚ÄúNCS‚Äù on the laboratory  
safet y test source document).
3. The participant may  be included in the study  if the abnormalit y is consistent 
with a pre -existing medical condition which is not excluded per protocol (eg, 
elevated eosinophil count in a participant with asthma or seasonal allergies),
the medical condition should be annotated on the laboratory report.
OR
4. The abnormal test may  be repeated (refer items a. and b. below for 
continuation of algorithm for repeated values).
a.If the repeat test value is within the normal range, the participant may 
enter the stud y.
b.If the repeat test value is still abnormal, the study  investigator will 
evaluate the potential participant with a complete history  and ph ysical 
examination, looking especiall y for diseases that could result in the 
abnormal laboratory  value in question. If such diseases can be ruled out, 
and if the abnormal laboratory  value is not clinically  relevant, then the 
participant may  enter the study .
D.If there is an y clinical uncertaint y regarding the significance of an abnormal value, the
participant will be excluded from the stud y.¬†
¬† 05JCP2
PRODUCT: MK-8591  97
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
10.11 Appendix 11: Abbreviations
Abbreviation Expanded Term
3TC Lamivudine
AE adverse event 
APaT All-Participants -as-Treated
AR adverse reaction
ART anti-retroviral therapy
ATP adenosine triphosphate
AIDS Acquired immunodeficiency syndrome
ALT Alanine aminotransferase
ART Anti-retroviral therapy
ARV Antiretroviral
AST Aspartate aminotransferase
AUC Area under the concentration -time curve
AUC0-24 Area Under the Curve from time 0 to 24 hours post dose
AUC0-inf Area Under the Curve from time 0 to infinity
AUC0-last Area Under the Curve from time 0 to last sampling time post dose
BDS blood drug screen
Œ≤-hCG Œ≤-human chorionic gonadotropin
BMI body  mass index
BP blood pressure
Bx biopsy
C24 Concentration at 24 hours post dose
C168 Concentration at 168 hours post dose
C672 Concentration at 672 hours post dose
Cmax Maximum concentration
CCC concordance correlation
CI confidence interval
CKD -EPI Chronic Kidney Dise ase Epidemiology Collaboration
CL clearance
CL/F Apparent clearance after extravascular administration
CrCl creatinine clearance
CRF Case Report Form 
CRU clinical research unit
CV coefficient of variation
DAIDS Division of AIDS
DILI drug-induced liver injury
DOR Doravirine 
DP Diphosphate 
DTG Dolutegravir 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
eCTA exploratory Clinical Trial Application
EDC electronic data collection 
eGFR estimated glomerular filtratio n rate
EMA European Medicines Agency
FBR Future biomedical research
FDA Food and Drug Administration 
FDC Fixed dose combination
FSH follicle stimulating hormone ¬†
¬† 05JCP2
PRODUCT: MK-8591  98
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Abbreviation Expanded Term
FTC Emtricitabine
GCP Good Clinical Practice 
GCV geometric coefficient of variation
GLP good laboratory practice
GM geometric mean
HBsAg Hepatitis B surface antigen
HBV Hepatit is B virus
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therapy
IB Investigator‚Äôs Brochure 
IC50 50% inhibitory concentration 
ICC intraclass correlation
ICF Informed Consent Form
ICH International C ouncilon Harmonization
IEC Independent Ethics Committee
I/E Inclusion/Exclusion
IMP investigational medicinal product
IND Investigational New Drug 
IRB Institutional Review Board
LNG/EE Levonorgestrel/ethinyl estradiol
MedDRA Medical Dictionary for Regulatory Activities
M4 metabolite M4
MCV Mean corpuscular volume
MCH Mean corpuscular hemoglobin
NIMP non-investigational medicinal product
NCS not clinically significant
NOAEL no observed adverse effect level 
NOEL No observed effect level
NRTI Nucleoside reverse transcriptase inhibitor
NNRTI Non-nucleoside reverse transcriptase inhibitor
NRTTI Nucleoside reverse transcriptase translocation inhibitor
PBMC Peripheral blood mononuclear cell
PK pharmacokinetic
PP Per-protocol
PrEP Pre-exposure prophylaxis
QD once -daily
QW once -weekly
RBC red blood cell 
RR Respiratory rate
SAC Scientific Advisory Committee
SAE serious adverse event 
SAP Statistical Analysis Plan
SD standard deviation 
SGOT Serum glutamic -oxaloacetic transaminase
SGPT Serum glutamic -pyruvic transam inase 
SoA schedule of activities
SOP Standard operating procedure 
t1/2 Half-life
TDF Tenofovir disoproxil fumarate
TK toxicokinetic
Tmax time of maximum concentration¬†
¬† 05JCP2
PRODUCT: MK-8591  99
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
Abbreviation Expanded Term
TP Triphosphate
UDS urine drug screen
VS vital sign
Vz/F Apparent volume of distribution during the terminal phase
WBC white blood cell 
WOCBP woman/ women of childbearing potential 
WONCBP woman/ women of non -childbearing potential¬†
¬† 05JCP2
PRODUCT: MK-8591  100
PROTOCOL/AMENDMENT N O.:026-02 
MK-8591 -026-02FINAL PROTOCOL 24-JUN-2020
11 REFERENCES
Not Applicable.¬†
¬† 05JCP2